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Abstract 
 
Factors associated with the initiation of biologic disease modifying 
antirheumatic drugs in Texas Medicaid patients with rheumatoid 
arthritis 
 
Gilwan Kim, M.S.Phr. 
The University of Texas at Austin, 2014 
 
Supervisor:  Jamie C. Barner 
 
Rheumatoid arthritis (RA) is a progressive autoimmune disorder of joints that is 
associated with high health care costs and yet lacks guidance on how early to initiate 
biologic disease-modifying antirheumatic drugs (DMARDs), a class of medications that 
is the major cost driver in RA management. The main purpose of this study was to 
examine patient socio-demographics, medication use patterns, and clinical characteristics 
associated with initiation of biologic DMARDs.  
This was a retrospective study using Texas Medicaid prescription and medical 
claims database during the study period of July 1, 2003 – December 31, 2010. Patients 
(18 – 63 years) with an RA diagnosis (ICD-9-CM code 714.xx), no non-biologic 
DMARD or biologic DMARD use during the pre-index period, and a minimum of 2 
 vii 
prescription claims for the same non-biologic DMARD during the post-index period were 
included in the study. The primary study outcomes were time to initiation of biologic 
DMARDs and likelihood of initiating biologic DMARDs.  
There was a total of 2,714 subjects included in the study. The majority had claims 
for pain medications (92.4%), glucocorticoids (64.9%), and non-biologic DMARD 
monotherapy (86.4%); while 24.3% initiated on biologic DMARDs and 58.9% had a 
Charlson Comorbidity Index (CCI) score=1. Compared to time to initiation (days) of 
biologic DMARDs for methotrexate (539.7±276.9) users, it was longer for sulfasalazine 
(670.2±167.8) and hydroxychloroquine (680.2±158.7) users and similar to leflunomide 
users (541.6±286.5; p<0.0001). There were no significant differences in time to initiation 
between non-biologic DMARD mono vs. dual therapy. Younger age, glucocorticoid use, 
methotrexate user (vs. sulfasalazine, hydroxychloroquine users), and non-biologic 
DMARD monotherapy user (vs. dual therapy user) were significantly associated with 
higher likelihood to initiate biologic DMARDs.  
In conclusion, age, glucocorticoid use, non-biologic DMARD type and therapy 
were significant factors associated with initiation of biologic DMARDs. Healthcare 
providers and Texas Medicaid should recognize these potential driving factors and take 
efforts to achieve optimal therapy for RA patients through thorough RA medication 
evaluation, well-structured RA monitoring programs, and patient education.  
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Chapter 1: Introduction and Literature Review 
 
1.1  PROBLEM STATEMENT 
Note: Please see Appendix A for a list of abbreviations. Rheumatoid arthritis 
(RA) is a progressive autoimmune disorder that is characterized by chronic inflammation 
of multiple joints, and it is the second most common arthritis after osteoarthritis.
1-4
 RA 
patients may experience a wide range of symptoms from joint stiffness, pain, swelling, 
and chronic joint deformities to extra-articular (i.e., ‘outside of the joint’) complications 
(e.g., rheumatoid nodules, vasculitis, pleural effusions, pulmonary fibrosis, pericarditis, 
bone marrow suppression).
5
 RA affects approximately 1.3 million adults in the United 
States.
6,7
 The prevalence of RA is approximately 0.3 – 1.0% among adults, and it is 
higher among older individuals (average age ~67), females, and those in developed 
countries.
6,8
 The etiology of RA is not clear, but potential risk factors include being 
female, oral contraceptive or tobacco use, and genetic factors.
1,9,10
 RA patients have 
lower quality of life as they often experience persistent pain as well as functional 
disability and psychological problems.
11
 Patients with established RA are known to have 
an average of two or more comorbidities, with cardiovascular disorders and pulmonary 
disorders (primarily infections) being most common.
12
 In addition, RA patients have a 
mortality rate 1.5 – 1.6 times higher than that of the general population.13 RA is an 
economic burden on employers and society. A recent study reported that U.S. employees 
with RA (N = 2,705) had average annual direct costs (i.e., medical and prescription costs) 
of $7,445 ($4,687 higher than those without RA; p < 0.0001) and indirect costs (i.e., sick 
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leave, short- and long-term disability, workers’ compensation absences) of $1,262 ($525 
higher than those without RA; p < 0.05) per patient. Based on this study, the total annual 
economic burden of RA to employers consisted of $5.8 billion ($5.2 billion in direct costs 
and $579 million in indirect costs), and 4.0 million incremental work loss days.
14
  
In RA management, medications are fundamental to treatment and can be divided 
into three categories:(1) symptomatic drugs (e.g., nonsteroidal anti-inflammatory drugs 
(NSAIDs), acetaminophen, opioid analgesics) help alleviate pain; (2) disease-modifying 
anti-rheumatic drugs (DMARDs), which are classified into non-biologic and biologic, 
reduce inflammation and joint damage, and (3) glucocorticoids (GCs) have both anti-
inflammatory and disease-modifying properties that help with symptom relief and 
mitigation of disease progression. The present study will focus primarily on non-biologic 
and biologic DMARDs. 
Non-biologic DMARDs, also known as “conventional DMARDs,” have been 
used to slow disease progression for decades. Examples of non-biologic DMARDs 
include methotrexate (MTX), sulfasalazine (SSZ), leflunomide (LEF), and 
hydroxychloroquine (HCQ).
15,16
 Biologic DMARDs are relatively new agents that have a 
significant effect on disease activity, functional capacity, and structural damage.
17,18
 
Biologic DMARDs are subcategorized into anti-tumor necrosis factor agents (i.e., 
adalimumab, etanercept, infliximab, certolizumab, golimumab), and non-tumor necrosis 
factor agents (i.e., abatacept, rituximab, tocilizumab). One significant difference between 
non-biologic and biologic DMARDs is cost. Non-biologic DMARDs costs range from 
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$30 to $900 monthly, whereas biologic DMARDs costs range from $2,000 to $5,000 
monthly.
19
 Current RA treatment guidelines agree that non-biologic DMARDs should be 
the first line therapy and should be initiated immediately upon diagnosis.
15,18
 MTX or 
LEF are usually the drugs of choice among non-biologic DMARDs. MTX has been a 
preferred drug because of its effectiveness and relatively low side effect profile with 
long-term use.
15,16
 If targeted outcomes are not achieved with non-biologic DMARD 
monotherapy, non-biologic DMARD combination therapy is recommended before 
moving to advanced therapy, which may include an addition of or switch to a biologic 
DMARD agent.
15,16
 
Few studies have explored prescription use patterns among RA patients using 
non-biologic DMARDs before advancing to biologic DMARDs. Adherence rates of non-
biologic DMARDs may impact initiation of biologic DMARDs. For example, if a patient 
is not adherent with his or her non-biologic DMARD, he or she may start on a biologic 
DMARD earlier than a patient who was adherent. Adherence rates varied from 30 – 
107% among several cross sectional and longitudinal studies. In general, adherence to 
MTX was higher than to other non-biologic DMARD monotherapy and MTX 
combination therapy. Several studies have shown that MTX users have longer medication 
persistence compared to other non-biologic DMARD users.
20-23
 In addition to adherence 
and persistence, socio-demographic factors (age, income, ethnicity/race, and insurance 
type) and clinical factors (comorbidities, disability, RA severity, and previous therapy 
with steroids or non-biologic DMARDs) may be associated with the initiation of biologic 
DMARDs.
24-26
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1.2 STUDY AIM 
This study aims to assess medication adherence and persistence of RA patients on 
non-biologic DMARD therapy, and to investigate the socio-demographic and clinical 
factors associated with initiation of biologic DMARD therapy.  
1.3 STUDY RELEVANCE 
This study may help clinicians and researchers better understand if specific non-
biologic DMARDs are associated with longer initiation time to biologic DMARDs 
among RA patients. In addition, understanding what patient demographic and clinical 
characteristics are associated with shorter time to use of biologic DMARDs may lead to 
interventions that lengthen the time horizon. For example, interventions to improve non-
biologic DMARD adherence and persistence may delay biologic DMARD use, which 
may lead to overall healthcare cost savings. Finally, the results from this study may be 
useful for future studies that address treatment protocols for patients with RA. 
1.4 LITERATURE REVIEW 
1.4.1 Definition, characteristics, and etiology of rheumatoid arthritis (RA) 
Rheumatoid arthritis (RA) is a progressive autoimmune disorder that is 
characterized by flares of inflammation of multiple joints, progressive joint erosion, and 
presence of autoantibodies.
1-3
 RA is the second most common arthritis after 
osteoarthritis.
4
 RA patients usually present with joint stiffness and pain, swelling, and 
chronic joint deformities. At more advanced disease stages, patients may also experience 
  5 
extra-articular complications (e.g., rheumatoid nodules, vasculitis, pleural effusions, 
pulmonary fibrosis, pericarditis, bone marrow suppression).
5
 Eighty percent of patients 
have poor prognosis and are expected to be disabled within 20 years from being 
diagnosed with RA.
27
 Patients are typically diagnosed with RA during their third to fifth 
decade of life, and RA affects approximately 1.3 million adults in the United States. 
While the exact cause of RA is unknown, potential risk factors include being female, oral 
contraceptive or tobacco use, and genetic factors.
1,9
 
1.4.2 Prevalence and incidence of RA 
RA prevalence is estimated at 0.3 – 1.0% of the adult population, with higher 
prevalence among older age groups, females, and in developed countries.
6
 RA prevalence 
decreased from 1.1% in 1985 to 0.6% in 2007, which is equivalent to 1.5 million adults in 
the U.S.
6,28
 From one study conducted in a Minnesota county, RA incidence and 
prevalence were shown to increase as age increased up to 74 years of age, and then it 
decreases afterwards. For prevalent RA, the average patient’s age increased from 63.3 
years in 1965 to 66.8 years in 1995.
6
 Incidence and prevalence are higher for females 
than for males (see Table 1.1).
6
 RA has been more prevalent among females throughout 
the years. Among men, prevalence was 0.41 per 100,000 in 2005; and among women, it 
was 0.98 per 100,000 in 2005.
28
 In one study of the civilian, non-institutionalized U.S. 
population, the age- and sex-adjusted prevalence of arthritis and multiple rheumatic 
conditions, including RA, was significantly lower among Hispanics (11.2 ± 1.0%) when 
compared to that of non-Hispanic whites (15.5 ± 0.3%) or non-Hispanic blacks (15.4 ± 
  6 
0.8%).
29
 While China (0.3%), Japan (0.09 per 1000 persons years), northwest Greece 
(0.15 – 0.36 per 1000 persons), and rural African countries (0.4 – 0.68%) are known to 
have lower prevalence of RA, Native Americans (2.4 – 7.1%) are reported to have higher 
prevalence.
30-36
 Furthermore, compared to the prevalence of RA in developed countries at 
0.3 – 1%, that of RA in developing countries remains at the lower end of the range (i.e., 
closer to 0.3%).
6
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Table 1.1. Annual incidence ratesa of RA in Olmsted County, Minnesota residents, 
1995 – 2007, by gender and age group 
 Male Female Total 
Age group 
(years) 
Patients 
(N) 
Rate Patients 
(N) 
Rate Patients 
(N) 
Rate 
18 – 34 7 3.6 27 13.8 34 8.7 
35 – 44 26 19.1 73 55.0 99 36.2 
45 – 54 30 26.9 72 62.4 102 44.9 
55 – 64 36 51.7 55 74.2 91 63.3 
65 – 74 31 72.4 51 104.4 82 89.4 
75 – 84 13 52.3 30 81.1 43 69.5 
≥ 85 2 26.1 13 63.7 15 53.5 
Total 
(95% CI) 
145 27.7 
(23.1, 
32.2)
b 
321 53.1 
(47.3, 
58.9)
b 
466 40.9 
(37.2, 
44.7)
c 
a
 Values are the annual incidence rates (95% confidence interval [95% CI] per 100,000 population) 
b
 Age-adjusted to the 2000 U.S. white population 
c
 Age- and sex-adjusted to the 2000 U.S. white population  
 
Source: Adapted from Myasoedova E, Crowson CS, Kremers HM et al. Is the incidence of rheumatoid 
arthritis rising?: Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010; 62(6); 1576-
1582. 
 
 
1.4.3  Morbidity, mortality and costs 
RA has a significant impact on individuals and society. Many RA patients have 
significant morbidities, such as persistent pain, functional disability, and psychological 
problems that impact multiple domains of their daily lives
37,38
 and that are associated 
with lower quality of life.
11
 The symptoms of RA may vary daily and are oftentimes 
unpredictable.
39
 Nearly 70% of RA patients have irreversible joint damage within a year 
of disease onset.
3
 Furthermore, the autoimmune nature of RA can lead to extra-articular 
complications (e.g., rheumatoid nodules, vasculitis, pleural effusions, pulmonary fibrosis, 
pericarditis, bone marrow suppression).
9
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Established RA patients are known to have an average of two or more 
comorbidities. RA patients’ functional status is related to the number of comorbidities, in 
addition to RA itself. Using data from the US National Data Bank for Rheumatic 
Diseases, Table 1.2 below shows the top five comorbidities associated with mortality, 
hospitalization, disability and medical costs among those with RA. Pulmonary disorders, 
cardiovascular diseases, and liver problems had the highest association with mortality, 
hospitalization and medical costs. Pulmonary disorders in RA may occur due to impaired 
immunity as well as drug toxicity from non-biologic DMARDs (i.e., SSZ, MTX, LEF) or 
biologic DMARDs (e.g, etanercept, infliximab, abatacept). Epidemiological studies have 
highlighted that RA may contribute to cardiovascular diseases (i.e., myocardial 
infarction, stroke) through systemic inflammation along with other classic cardiovascular 
risk factors (i.e., hypertension, dyslipidemia, insulin resistance).
12
 Liver problems may be 
caused by medication hepatotoxicity or in rare cases, via RA’s extra-articular 
manifestations.
40
 In addition, RA medications such as glucocorticoids (GCs) and anti-
TNF therapy are also known to contribute to increased risk of infections, particularly in 
the lungs, because of their immunosuppressive properties.
12
 RA patients, especially those 
in active and severe states, are more susceptible to bacterial, tubercular, fungal, 
opportunistic and viral infections. Depression had the highest association with all three 
types of disability (i.e. social security, work, Health Assessment Questionnaire (HAQ)). 
Other significant comorbidities include fracture (due to bone erosion) and GI disorders 
(due to increased use of GCs and NSAIDs).
12
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The number of comorbidities is an important factor in determining prognosis. As 
shown in Table 1.3, various comorbidity scoring systems are used to assess disease 
severity, health status, mortality and morbidity. The scoring systems assign different 
weights to each disease state, which reflect that varying comorbidity weights result in 
varying prognoses.  
 
Table 1.2.  Ranked importance of comorbid conditions for specific outcomes in patients 
with RA 
 
Outcome 
Comorbid conditions (ranked importance) 
1 2 3 4 5 
Mortality Lung
a 
MI Fracture Stroke Diabetes 
Hospitalization MI Lung Other CVD Hypertension Depression 
SS disability Depression Fracture Lung Diabetes Ulcer 
Work 
disability 
Depression Diabetes Lung Hypertension Non-ulcer GI 
HAQ disability Depression Fracture Diabetes Ulcer Non-ulcer GI 
Medical costs Lung Liver Diabetes Hypertension Other CVD 
CVD, cardiovascular disease; GI, gastrointestinal; HAQ, Health Assessment Questionnaire; MI, 
myocardial infarction; SS, US social security 
a
Pulmonary disorders 
Source: Adapted from Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin 
Rheumatol; 2007; 21(5); 885-906. 
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Table 1.3. Comorbidity indices and use 
Index  Content Use 
Charlson Comorbidity Index 
(CCI) 
19 weighted CCs at 
hospital admission 
Mortality 
Kaplan/Feinstein Rated severity (0 – 3) of 
cogent CCs 
Mortality 
Chronic Disease Score 
(CDS) 
Pharmacy data weighted 
for prescription 
medications 
Disease severity, health 
status, mortality, 
hospitalization 
Index of Co-Existent 
Disease (ICED) 
Rated severity (0 – 4) of 
worst CC at hospital 
admission 
Functional outcome, post-
hospital complications 
Cumulative Illness Rating 
Scale (CIRS) 
Sum of 14-organ system 
reviews by severity (0 – 4) 
Level of overall CCs 
Functional Comorbidity 
Index (FCI) 
Sum of 18 CCs Physical function 
Michaud/Wolfe 
(unpublished data) 
11 weighted CCs from 
patient report 
Mortality, hospitalization, 
work and functional 
disability, medical costs 
CC, comorbid condition 
Source: Adapted from Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin 
Rheumatol; 2007; 21(5); 885-906. 
 
 
When RA patients are left untreated, they can experience severe disability and 
premature mortality.
41
 Sokka et al. showed that the mortality rates among those with RA 
were 1.5 – 1.6 times higher than the general population. While the overall mortality rates 
of the general population have improved over the last 4 years, one study reported that this 
does not hold true for RA patients.
13
 Furthermore, RA is estimated to account for 22% of 
all deaths from arthritis and other rheumatic conditions.
42
 
There is significant work productivity loss associated with RA. Approximately 
80% of working-age RA adult patients have disabling pain, stiffness and declined 
functional ability, in addition to restricted ability to perform social roles.
3
 A review 
demonstrated that a median of 66% (range 36% – 84%) of employed RA patients had 
  11 
work loss because of RA in the previous 12 months, for a median time period of 39 days 
(range 7 – 84 days). For 50% of RA patients, work loss occurred between 4.5 – 22 years 
after diagnosis.
43
 RA patients with more severe disease experienced higher work 
productivity loss.
44
 The risk of future productivity loss was predicted by lower education 
level (< 10 years of education) [Reference group: ≥ 14 years of education, Odds Ratio 
(OR) = 2.40, 95% CI = 1.18 – 4.88], higher patient’s global assessments of RA severity 
(severe RA ≥ 50 out of 100) [Reference group: score of < 50, OR = 1.77, 95% CI = 1.00 
– 3.16], and higher self-reported disability Health Assessment Questionnaire score 
(higher disability ≥ 1.0 out of 3.0) [Reference group: score of < 1.0, OR = 1.85, 95% CI = 
1.03 – 3.32].45 A recent study reported that the U.S. employees with RA (N = 2,705) had 
average annual direct costs (i.e., medical and prescription costs) of $7,445 ($4,687 higher 
than those without RA; p < 0.0001) and indirect costs (i.e., sick leave, short- and long-
term disability, workers’ compensation absences) of $1,262 ($525 higher than those 
without RA; p < 0.05) per patient. Based on this study, the total annual economic burden 
of RA consists of $5.8 billion ($5.2 billion in direct costs and $579 million in indirect 
costs), and 4.0 million incremental work loss days.
14
 As RA progresses to more severe 
stages, indirect costs increase, which leads to increased likelihood of unemployment.
46,47
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1.4.4 Disease progression and classification of RA 
Next, RA progression and classification will be discussed as they are important in 
determining treatment strategies. RA is an autoimmune disorder in which progression is 
driven by autoimmunity and the inflammatory process.
41
 This disorder is defined by three 
interrelated factors: disease activity, joint damage, and disability.
17
 As shown in Table 
1.4, several different scales are available to measure disease activity, which is a 
composite score of factors (e.g., joint tenderness or swelling, erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP)). Each scale categorizes the disease progression into 
four stages: remission, low activity, moderate activity, and high activity.
15,17
 One study 
demonstrated that disease activity level and duration of remission influenced subsequent 
joint damage. Even after a period of remission, a carry-over effect from the previous 
inflammation remains, thus possibly leading to further progression of the disease and 
resulting in joint damage. The shorter the duration of remission, the more RA progression 
is likely to occur.
48
 While disease activity is reversible, joint damage is irreversible and 
manifests the destructive nature of RA. Disability reflects the overall RA state 
characterized by physical function and quality of life.
17
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Table 1.4. Scales to measure RA disease activity levels
15
 
Scales Disease Activity Levels 
Patient Activity Scale or PAS-II
49
 
(range 0 – 10) 
Remission: 0 to 0.25 
Low activity: > 0.25 to 3.7 
Moderate activity: > 3.7 to < 8.0 
High activity: ≥ 8.0 
Routine Assessment of Patient Index Data 3
50
 
(range 0 – 10) 
Remission: 0 to 1.0 
Low activity: > 1.0 to 2.0 
Moderate activity: > 2.0 to 4.0 
High activity: >4.0 to 10 
Clinical Disease Activity Index
51
 
(range 0 – 76.0) 
Remission: ≤ 2.8 
Low activity: > 2.8 to 10.0 
Moderate activity: > 10.0 to 22.0 
High activity: > 22.0 
Disease Activity Score in 28 joints
52
 
(range 0-9.4)  
Remission: < 2.6 
Low activity: 2.6 ≤ to < 3.2 
Moderate activity: ≥ 3.2 to ≤ 5.1 
High activity: >5.1 
Simplified Disease Activity Index
51
 
(range 0 – 86.0) 
Remission: ≤ 3.3 
Low activity: > 3.3 to ≤ 11.0 
Moderate activity: > 11.0 to ≤ 26 
High activity: >26 
 
As with many other disease states, RA has classification criteria to monitor and 
treat the disease appropriately. The 1987 American College of Rheumatology (ACR) 
classification criteria (not shown in Table 1.4) mainly focused on clinical symptoms and 
laboratory test results to identify patients with  RA.
53
 While it was a useful tool to screen 
for RA, it was limited in classifying patients during the early stages of RA. In 2010, a 
joint working group comprised of the ACR and European League Against Rheumatism 
(EULAR) introduced new criteria to both identify and classify RA. The 2010 ACR-
EULAR classification criteria highlight the importance of the “window of opportunity,” 
which aims to identify RA earlier and to initiate treatment earlier for better outcomes (see 
Table 1.5).
41
 One study demonstrated that the updated 2010 classification criteria 
  14 
classified more patients earlier than the 1987 ACR criteria.
54
 Subsequently, the ACR – 
EULAR classification criteria was used as a foundation when establishing the updated 
2012 RA treatment guidelines in which RA is classified into early and established stages. 
The early and established stages are defined as having disease duration of less than 6 
months and 6 months and longer, respectively.
15
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Table 1.5. The 2010 ACR-EULAR classification criteria for RA
a,b
 
Criteria Score 
1. Joint involvementc 
1) 1 large jointd 
2) 2-10 large joints 
3) 1-3 small joints (with or without involvement of large joints)e 
4) 4-10 small joints (with or without involvement of large joints) 
5) > 10 joints (at least 1 small joint)f 
 
0 
1 
2 
3 
5 
2. Serology (at least 1 test result is needed for classification)g 
1) Negative RF and negative ACPA 
2) Low-positive RF or low-positive ACPA 
3) High-positive RF or high-positive ACPA 
 
0 
2 
3 
3. Acute-phase reactants (at least 1 test result is needed for 
classification)h 
1) Normal CRP and normal ESR 
2) Abnormal CRP or abnormal ESR 
 
0 
1 
4. Duration of symptomsi 
1) < 6 weeks 
2) ≥ 6 weeks 
 
0 
1 
ACPA = anti-citrullinated protein antibody; CRP = C-reactive protein; ESR = erythrocyte sedimentation 
rate; RF = rheumatoid factor 
Note: Patients who have at least 1 joint with definite clinical synovitis and/or with the synovitis not better 
explained by another disease should be tested for RA.
a 
A patient is classified as having definite RA if 
their score is ≥ 6 (out of 10)b 
a 
Differential diagnoses vary among patients with different presentations, but may include conditions such 
as systemic lupus erythematosus, psoriatic arthritis, and gout. If it is unclear about the relevant 
differential diagnoses to consider, an expert rheumatologist should be consulted. 
b
 Although patients with a score of <6/10 are not classifiable as having RA, their status can be reassessed 
and the criteria might be fulfilled cumulatively over time. 
c
 Joint involvement refers to any swollen or tender joint on examination, which may be confirmed by 
imaging evidence of synovitis. Distal interphalangeal joints, first carpometacarpal joints, and first 
metatarsophalangeal joints are excluded from assessment. Categories of joint distribution are classified 
according to the location and number of involved joints, with placement into the highest category 
possible based on the pattern of joint involvement. 
d
 "Large joints" refers to shoulders, elbows, hips, knees, and ankles. 
e
 "Small joints" refers to the metacarpophalangeal joints, proximal interphalangeal joints, second through 
fifth metatarsophalangeal joints, thumb interphalangeal joints, and wrists. 
f 
In this category, at least 1 of the involved joints must be a small joint; the other joints can include any 
combination of large and additional small joints, as well as other joints not specifically listed elsewhere 
(e.g., temporomandibular, acromioclavicular, sternoclavicular, etc.). 
g
 Negative refers to IU values that are less than or equal to the upper limit of normal (ULN) for the 
laboratory and assay; low-positive refers to IU values that are higher than the ULN but ≤3 times the ULN 
for the laboratory and assay; high-positive refers to IU values that are >3 times the ULN for the 
laboratory and assay. Where RF information is only available as positive or negative, a positive result 
should be scored as low-positive for RF.  
h
 Normal/abnormal is determined by local laboratory standards.  
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i
 Duration of symptoms refers to patient self-report of the duration of signs or symptoms of synovitis (e.g., 
pain, swelling, tenderness) of joints that are clinically involved at the time of assessment, regardless of 
treatment status. 
Source: Adapted from https://ww2.rheumatology.org/practice/clinical/classification/ra/ra_2010.asp 
 
1.4.5 RA treatment  
1.4.5.1 Pharmacologic therapy 
Regarding RA therapy, medications are considered fundamental to treatment (see 
Table 1.6). Pharmacologic therapy can be divided into three categories: (1) symptomatic 
medications (e.g., nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, 
opioid analgesics), (2) disease-modifying anti-rheumatic drugs (non-biologic and 
biologic DMARDs), and (3) glucocorticoids (GCs). This section will provide a brief 
overview of each category.  
Symptomatic medications 
Symptomatic medications can be classified into two subgroups: non-opioid 
analgesics and opioid analgesics. Among non-opioid analgesics, NSAIDs, which are 
cyclooxygenase (COX) (i.e., nonspecific COX or COX-2) inhibitors, have antipyretic, 
analgesic, and anti-inflammatory properties. They are usually indicated to relieve mild to 
moderate pain, and administered orally or rectally. Common side effects include 
gastrointestinal (GI) effects (e.g., heartburn, nausea, vomiting) and dizziness. 
Acetaminophen is another non-opioid analgesic that has analgesic and antipyretic 
properties, but not anti-inflammatory effects. The drug is proposed to inhibit COX-3 in 
the central nervous system. It can be administered orally, rectally, or intravenously, and 
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its side effects are nausea and vomiting. Opioid analgesics, which interact with opioid 
receptors, are approved for moderate to severe pain, and administered orally, 
transdermally, rectally, vaginally, topically, and intravenously. Common side effects 
include constipation, nausea, vomiting, and dizziness. Unlike the non-opioid medications, 
opioid analgesics can produce tolerance and physical dependence.
55,56
 
Disease-modifying antirheumatic drugs (DMARDs) 
DMARDs are classified into non-biologic and biologic. Non-biologic DMARDs, 
which have been available for decades, help alleviate RA symptoms, reduce joint 
damage, and help with disease remission.
17
 Among non-biologic DMARDs, MTX, an 
antimetabolite that interferes with cellular replication, is usually the drug of choice as 
monotherapy in the early stage or as part of combination therapy in advanced stages 
because of its effectiveness and relatively low side effect profile with long-term use. The 
drug is usually given orally once weekly. Common side effects include liver alopecia, 
oral ulcers, cytopenias, nausea, and vomiting.
15,16
 According to the Treatment of Early 
Rheumatoid Arthritis (TEAR) trial, 30% of RA patients with early, poor prognosis were 
shown to respond well to MTX monotherapy and had comparable results to step up 
combination therapy (i.e., MTX + etanercept or MTX + SSZ + HCQ) at 2 years.
57
 Other 
non-biologic DMARDs include LEF, HCQ, and SSZ. LEF is an immunomodulatory, 
antiproliferative, and anti-inflammatory agent that is given orally once daily, and its side 
effects include rash, diarrhea, respiratory tract infection, and agranulocytosis.
19
 HCQ, an 
antimalarial with unknown mechanism of action for RA, is given orally once daily. Its 
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side effects include disorder of the cornea, torsades de pointes, neuromyopathy, and 
hearing loss.
19
 SSZ also has an unknown mechanism of action and is given orally once 
daily as an initial dose followed by twice daily as a maintenance dose. Some common 
side effects include rash, abdominal pain, loss of appetite, headache, and hepatotoxicity.
19
 
Biologic DMARDs are relatively new agents that are known to have a significant 
effect on disease activity, functional capacity, and structural damage.
17,18
 Biologic 
DMARDs can be categorized into anti-tumor necrosis factor (TNF) and non-TNF agents. 
The following are anti-TNF agents: etanercept, infliximab, adalimumab, certolizumab, 
and golimumab. Anti-TNF agents prevent part of the cascade that leads to RA by 
blocking TNF-α’s binding to its receptor. Common adverse events include injection-site 
or infusion reactions, infections, and malignancy. Regarding non-TNF agents (i.e., 
anakinra, tocilizumab, abatacept, and rituximab), each has a different mechanism of 
action such as Interleukin (IL)-1 and IL-6 inhibition, T-cell costimulation blockade and 
B-cell target. Even though anti-TNF and non-TNF agents have different mechanism of 
actions, their adverse effects are similar. Also, both have relatively long half-lives (4 – 19 
days). While abatacept, a non-TNF agent, was approved as a first-line biologic DMARD 
in the U.S., some patients do not respond as rapidly as with anti-TNF agents. As shown in 
Table 1.6 below, there are more anti-TNF agents available than non-TNF agents. The 
latter agents are reserved for use in patients with established RA and high disease 
activity.
58
 Note: Adalimumab, etanercept, and infliximab were approved by the FDA 
between 1998-2002, which was prior to the present study’s timeframe, while other agents 
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(i.e., certolizumab, golimumab, abatacept, rituximab, tocilizumab) were approved 
between 2005-2010, which was during the present study’s timeframe. 
Biologic DMARDs are shown to have greater efficacy when combined with MTX 
or other non-biologic DMARDs.
16
 Because of high costs, biologic DMARDs are usually 
reserved for advanced stage RA after other options have been utilized. Non-biologic 
DMARD costs range from $30 to $900 monthly, whereas biologic DMARD costs range 
from $2,000 to $5,000 monthly.
19
  
Glucocorticoids (GCs) 
GCs have both anti-inflammatory and disease-modifying properties. GCs, which 
can be administered orally, intra-articularly or intramuscularly, are usually given in 
combination with non-biologic DMARDs to slow down the progression of bone erosion. 
Low dose (5 – 10 mg/day) GCs are usually added to DMARDs (typically for up to 2 
years), but higher doses are used for faster improvement and they are typically tapered 
within 6 to 8 months.
16,59
 Low to medium dose of oral GCs, high dose of intramuscular 
GCs, or intravenous bolus GCs are usually used when patients wait for a non-biologic 
DMARD to take effect.
60,61
 Intra-articular GC therapy is standard for patients with 
polyarticular disease activity.
62
 Because of its long-term adverse effects (e.g., 
cardiovascular risk), GCs are recommended for short-term use, and the dosage needs to 
be determined after weighing the benefits and risks.
16,63
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Table 1.6. Pharmacological therapeutic options for RA by drug class
5,15
 
Symptomatic Medications 
Non-opioid analgesics Nonselective nonsteroidal anti-inflammatory drugs 
(NSAIDs): 
Aspirin, celecoxib, diclofenac, etodolac, fenoprofen, 
flurbiprofen, ibuprofen, indomethacin, meclofenamate, 
meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, 
sulindac, tolmetin 
Acetaminophen 
Opioid analgesics Codeine, hydrocodone, oxycodone, fentanyl, 
hydromorphone, meperidine, methadone, morphine, 
propoxyphene, tramadol  
Disease Modifying Anti-Rheumatic Drugs (DMARDs) 
Non-biologic DMARDs Methotrexate (MTX), sulfasalazine (SSZ), leflunomide 
(LEF),  hydroxychloroquine (HCQ) 
Biologic DMARDs
a 
Anti-TNF: 
Adalimumab, certolizumab, etanercept, infliximab, 
golimumab 
Non-TNF: 
Abatacept, rituximab, tocilizumab 
Glucocorticoids (GCs) 
 Prednisone, prednisolone, methylprednisolone 
a 
Approval dates: adalimumab (12/2002); certolizumab (5/2009); etanercept (11/1998); infliximab 
(11/1999); golimumab (4/2009); abatacept (12/2005); rituximab (3/2006); tocilizumab (1/2010) 
TNF,  necrosis factor 
 
 
1.4.5.2 Non-pharmacologic therapy 
Conventional therapies and surgical procedures are also used to treat RA. 
Examples of conventional therapies include: physical therapy, occupational therapy, 
comprehensive rehabilitation, self-management programs including cognitive behavioral 
approaches, and assistive devices such as wrist and finger splints and foot orthotics. In 
addition, many RA patients depend on a wide range of complementary and alternative 
medicine (e.g. herbs, vitamins, yoga, homeopathy, acupuncture).
39,64
 In cases of 
significant functional impairment and pain, reconstructive surgery may be considered for 
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selected RA patients.
65
 Among RA patients, 17% will have an orthopedic intervention in 
5 years of RA diagnosis, and over 33% will undergo a major joint replacement.
27
 
 
1.4.6 Overview of current RA treatment guidelines 
Among several different sets of clinical guidelines available for managing RA, the 
ACR and the EULAR RA therapy management guidelines are the most utilized. This 
section will focus on the overarching principles of each set of guidelines and 
recommendations regarding transitioning from non-biologic DMARDs to biologic 
DMARDs.  
1.4.6.1 American College of Rheumatology (ACR) treatment guidelines 
In 2012, the ACR updated RA therapy management guidelines to address early 
stage RA (Figure 1.1) and established stage RA (Figure 1.2). The basic principles in the 
guidelines are to: a) reach low disease activity or remission as soon as possible; b) 
achieve tighter control of the disorder by frequent assessments every 1 – 3 months; and c) 
make therapy adjustments every 3 – 6 months.15 According to the guideline, MTX or 
LEF (i.e., non-biologic DMARDs) are the first drugs of choice for most patients. After 
non-biologic DMARD monotherapy, patients are usually stepped up to non-biologic 
DMARD combination therapy before moving to advanced therapy, which may include an 
addition of or switch to a biologic DMARD agent.
15
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Figure 1.1. Treatment guidelines for early RA (disease duration < 6 months) from the 
2012 American College of Rheumatology recommendations update 
 
 
 
DMARD (disease-modifying antirheumatic drug) indicates non-biologic DMARD and includes 
hydroxychloroquine (HCQ), leflunomide (LEF), methotrexate (MTX), minocycline, and sulfasalazine 
Anti-TNF (anti–tumor necrosis factor) indicates biologic DMARD and includes adalimumab, certolizumab, 
etanercept, infliximab, golimumab 
* Disease activity – categorized as low, moderate, and high according to validated scales (see Table 2)  
† Patients were categorized based on the presence or absence of 1 or more of the following poor prognostic 
features: functional limitation, extraarticular disease, positive rheumatoid factor or anti– cyclic citrullinated 
peptide antibodies, and bony erosions by radiograph. 
‡ Combination non-biologic DMARD therapy with 2 non-biologic DMARDs is most commonly MTX 
based. 
Source: Adapted from Singh JA, Furst DE, Bharat A et al. 2012 Update of the 2008 American College of 
Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic 
Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care & Research 2012; 64 (5): 625-639. 
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Figure 1.2. Treatment guidelines for established RA (disease duration ≥ 6 months) from 
the 2012 American College of Rheumatology recommendations update 
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In the diagram, DMARD refers to non-biologic DMARD   
Non-biologic DMARD (disease-modifying antirheumatic drug) (includes hydroxychloroquine [HCQ], 
leflunomide [LEF], methotrexate [MTX], minocycline, and sulfasalazine); anti-TNF = anti–tumor necrosis 
factor. 
* Disease activity – categorized as low, moderate, and high according to validated scales (see Table 2)  
† Patients were categorized based on the presence or absence of 1 or more of the following poor prognostic 
features: functional limitation, extraarticular disease, positive rheumatoid factor or anti– cyclic citrullinated 
peptide antibodies, and bony erosions by radiograph. 
§ Reassess after 3 months and proceed with escalating therapy if moderate or high disease activity in all 
instances except after treatment with a non-TNF biologic (rectangle D), where reassessment is 
recommended at 6 months due to a longer anticipated time for peak effect. 
¶ LEF can be added in patients with low disease activity after 3–6 months of minocycline, HCQ, MTX, or 
sulfasalazine. 
# If after 3 months of intensified non-biologic DMARD combination therapy or after a second non-biologic 
DMARD has failed, the option is to add or switch to an anti-TNF biologic. 
** Serious adverse events were defined per the US Food and Drug Administration (FDA; see ‡‡below); all 
other adverse events were considered nonserious adverse events. 
†† Reassessment after treatment with a non-TNF biologic is recommended at 6 months due to anticipation 
that a longer time to peak effect is needed for non-TNF compared to anti-TNF biologics. 
‡‡ Any adverse event was defined as per the US FDA as any undesirable experience associated with the 
use of a medical product in a patient. The FDA definition of serious adverse event includes death, life-
threatening event, initial or prolonged hospitalization, disability, congenital anomaly, or an adverse event 
requiring intervention to prevent permanent impairment or damage. 
 
Source: Adapted from Singh JA, Furst DE, Bharat A et al. 2012 Update of the 2008 American College of 
Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic 
Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care & Research 2012; 64 (5): 625-639. 
 
 
1.4.6.2 European League Against Rheumatism (EULAR) treatment guidelines 
The 2010 EULAR guidelines have a set of recommendations (Figure 1.3) and a 
treatment algorithm (Table 1.7) regarding RA management including non-biologic and 
biologic DMARDs use. Non-biologic DMARDs are recommended to be initiated when 
RA is diagnosed. The following patients are recommended to consider a biologic 
DMARD: those who have poor prognostic factors and do not meet treatment targets with 
the first non-biologic DMARD, those who respond to MTX (with or without non-
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biologic DMARDs) inadequately, and DMARD-naïve patients with poor prognostic 
factors. Furthermore, the guideline recommends that every patient be considered for 
intensive medication strategies. According to the EULAR guideline, even though GCs 
are advantageous with disease-modifying effects, they are recommended to be used for 
short-term (no specific time period mentioned) to avoid any long-term adverse effects. 
The guidelines do not explicitly recommend whether to use high or low dose GCs.
16
 
While the two sets of guidelines have different treatment algorithms, both share a 
few key points. They hold the fundamental principle that for better outcomes: RA 
patients should be treated with non-biologic DMARDs as soon as they are diagnosed, and 
clinicians should aim for remission or low disease activity as soon as possible. When 
choosing a non-biologic DMARD, MTX is a preferred choice in both of the guidelines. 
Medications should be monitored and reassessed every 1 – 3 months. When adjusting 
therapy, patients are usually stepped up from non-biologic monotherapy to non-biologic 
DMARD combination therapy before adding or switching to a biologic DMARD. 
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Figure 1.3. Algorithm based on the EULAR recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Adapted from Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the 
management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic 
drugs. Ann Rheum Dis 2010; 69(6), 964-975. 
 
Such as RF/ACPA, especially at high 
levels; 
Very high disease activity; 
Early joint damage 
± ± 
Biologic DMARD ± non-biologic 
DMARD 
Failure phase II:  
Go to phase III 
Prognostically unfavorable factors present Prognostically unfavorable factors absent 
No contraindications for MTX 
Phase I 
Continue 
Start LEF, 
intramuscular gold 
or SSZ 
Combine with 
short-term low or 
high dose GCs 
Start MTX 
Change the biologic DMARD: 
Switch to 2nd TNF inhibitor  
(+ non-biological DMARD) 
Or 
Replace TNF inhibitor by  
abatacept (+ non-biological DMARD) 
or 
rituximab (+ non-biological DMARD) 
or 
tocilizumab (+ non-biological 
DMARD) 
 
 
 
 
Start a second non-biologic DMARD: 
LEF, SSZ, MTX or intramuscular gold as 
monotherapy or eventually as combination 
therapy  
(with or without addition of GCs as above) 
Add a biologic DMARD 
(especially a TNF-
inhibitor) 
No 
No 
No 
No 
Yes 
Yes 
Yes 
Continue 
Continue 
Achieve target 
within 3-6 months 
Achieve target 
within 3-6 months 
Achieve target 
within 3-6 months 
Achieve target 
within 3-6 months 
Failure or lack of 
efficacy and/or 
toxicity in phase II 
Failure or lack of 
efficacy and/or 
toxicity in phase I 
Clinical diagnosis 
of rheumatoid 
arthritis 
Contraindications for MTX 
Failure phase I:  
Go to phase II 
Phase II 
Phase III 
  27 
Table 1.7. Non-biologic DMARD-based monotherapy, dual therapy and triple therapy 
options based on the EULAR recommendations
16
 
Monotherapy Medications 
Phase I First line: MTX 
Second line: LEF, gold, or SSZ (if MTX is contraindicated) 
 
Phase II 2
nd
 non-biologic DMARD (when the 1
st
 non-biologic DMARD failed) 
 
Phase III  Biologic DMARD (change the biologic component)  
 
Dual therapy  
Phase I First line: MTX+ GC 
Second line: LEF, gold, or SSZ + GC 
 
Phase II Non-biologic DMARD combination (2 non-biologics) 
 
Phase III Biologic DMARD + non-biologic DMARD  
 
Triple therapy   
Phase II First line: non-biologic DMARD combination (2 non-biologics) + GC 
Second line: non-biologic DMARD combination (2 non-biologics) + 
biologic (TNF inhibitor) 
 
Phase III Non-biologic DMARD combination (2 non-biologics) + biologic (TNF 
inhibitor) + GC 
 
Phase I is when clinical diagnosis of RA has initially been made  
Phase II is when failure to, lack of efficacy of, or toxicity of Phase I therapy occurred  
Phase III is when failure to, lack of efficacy of, or toxicity of Phase II therapy occurred 
MTX, methotrexate; LEF, leflunomide; SSZ, sulfasalazine; DMARD, disease-modifying antirheumatic drug; GC, 
glucocorticoid; TNF, tumor-necrosis factor  
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1.4.7 RA medication use patterns 
Medication adherence and persistence are critical in maintaining therapeutic 
benefit from medications and preventing adverse outcomes and higher costs of care 
associated with nonadherence. Especially with RA patients, early treatment and 
maintenance of therapy are important to avoid further disease progression and achieve 
remission or lower disease activity as soon as possible. Below is an overview of 
adherence and persistence in general, followed by adherence and persistence with non-
biologic therapies among RA patients. 
1.4.7.1 Overview of medication adherence and persistence 
Medication adherence is defined as “active, voluntary, and collaborative 
involvement of the patient in a mutually acceptable course of behavior to produce a 
therapeutic result.”66 It measures the degree to which a patient follows his or her 
healthcare provider’s recommendations in regards to prescribed timing, dose, and 
frequency. Medication persistence is defined as the act of resuming medications for the 
prescribed time period.
67
 Studies show that 50% of the annual prescriptions dispensed are 
not taken as prescribed. Approximately 125,000 deaths and 33 – 69% of medication-
related hospital admissions occur from medication nonadherence. In economic terms, 
nonadherence direct and indirect costs are between $100 billion and $300 billion 
annually. Patients with chronic diseases are reported to be adherent to their medications 
only 50 – 60% of the time.68 Adherence rates in patients with acute conditions are usually 
higher than those with chronic conditions.
69
 Regarding overall RA medication adherence, 
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greater self-efficacy, better patient-health care professional relationship, more social 
support, and older age have been shown to be associated with improved RA medication 
adherence.
70-74
 
 
1.4.7.2 Non-biologic DMARD adherence and persistence in RA patients  
Non-biologic DMARD adherence 
Adherence to non-biologic DMARDs will be reviewed in this section. Patients 
who have little efficacy or increased adverse effects from non-biologic DMARDs are 
more likely to not adhere to therapy. Patients who are not adherent to non-biologic 
DMARDs may be more likely to initiate biologic DMARD therapy. Two review studies 
by Salt et al (2010) and van den Bemt et al (2012), respectively, revealed that rates of 
adherence to non-biologic DMARDs varied from 33 – 107% among four cross sectional 
and longitudinal studies. 
73,78-80
 Salt et al. examined 35 studies that were not limited to 
non-biologic DMARD adherence. Some studies assessed patients’ beliefs about 
medication taking and persistence in biologic DMARDs. On the other hand, van den 
Bemt et al. examined 19 studies that evaluated medication adherence rates and factors 
associated with adherence. In both reviews, most studies did not specify DMARD type or 
investigated irrelevant medications (i.e., biologic DMARDs, D-penicillamine). There 
were only four studies that were relevant to non-biologic DMARD adherence.
70,75-77
 The 
wide variation in adherence rates could be due to: study design, sample size differences, 
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heterogeneous patient populations, follow-up period variations, medications studied and 
varied adherence measurement methods.
78
  
Because of similarities to the present study, which used Texas Medicaid, two 
retrospective database studies using Tennessee Medicaid will be reviewed in more detail 
below. Among Tennessee Medicaid enrollees (N=10,547) who had a new episode of non-
biologic and/or biologic DMARD regimens between 1995 – 2004, mean adherence 
(MPR, Medication Possession Ratio) rates of non-biologic DMARDs (i.e., MTX, HCQ, 
SSZ, LEF, MTX + HCQ) were between 66% (SD not available) for MTX + HCQ and 
85% (SD not available) for LEF, after one year follow-up. The study sample was mostly 
female (80%), white (72%), and aged 41 – 66.75 A later (1995-2005) Tennessee Medicaid 
managed care study using a retrospective cohort of RA patients with a shorter follow-up 
period (180 days vs. 1 year) revealed lower median adherence rates, ranging from 33% to 
69%, for MTX, HCQ, LEF, and SSZ. While SSZ had the lowest median adherence of 
33%, LEF had the highest median adherence of 69%.
76
 Note: adherence rates may have 
been lower in this study because the previous study reported means, while this study 
reported medians.  
In another longitudinal study that included RA, polymyalgia rheumatica, or gout 
patients (N=127) at an outpatient rheumatology clinic in the Netherlands, adherence was 
assessed using Medication Event Monitoring Systems (MEMS). Of the total sample, 81 
patients had RA and were taking NSAIDs and non-biologic DMARDs (i.e., SSZ, MTX). 
Three types of compliance were measured: “taking compliance”, which was the 
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percentage of taking doses as prescribed during a study period, “correct dosing”, which 
was the percentage of correct number of doses taken during a study period, and “timing 
compliance”, which was the proportion of: the number of interdose-intervals (i.e., in-
between dose interval ± 25%) of allowed period / the number of prescribed interdose-
intervals. Patients on MTX (once-weekly dosing) had 107% (98 – 117%) taking, 81% (75 
– 87%) correct dosing and 83% (76 – 90%) timing compliance, while patients on SSZ 
(twice-daily dosing) had 72% (60 – 84%) taking, 55% (44 – 67%) correct dosing and 
25% (18 – 33%) timing compliance, respectively. SSZ adherence may have been lower 
because of a more frequent dosing schedule. The study subjects were mostly female 
(66%) and aged 60 ± 14 years.
70
 In a randomized, controlled, assessor-blinded clinical 
trial, adherence was measured using pill counts. Brus et al. showed that adherence rates 
for SSZ were 82% and 91% for study periods 0 – 3 months and 3 – 6 months, 
respectively.
77
  
Individual adherence comparisons were difficult with other studies because they 
did not specify non-biologic DMARD type or they reported combined NSAID and non-
biologic DMARD adherence together. Interview-based studies reported adherence rates 
between 30% and 68% for non-biologic DMARDs and NSAIDs.
74,79-81
 Overall, of the 
few studies conducted, there is a wide range of non-biologic DMARD adherence rates 
among RA patients regardless of measurement methods or medication type. 
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Non-biologic DMARD persistence 
Regarding persistence or discontinuation of non-biologic DMARDs, several 
studies have shown that MTX users have longer medication persistence compared to 
other non-biologic DMARD users.
20-23
 Also, the majority of the studies did not report a 
gap period with persistence estimates. In a cross-sectional study that had a mean follow-
up duration of 100.5 ± 69.4 months, Agarwal et al. showed that the median medication 
persistence periods (or retention rates), which were estimated by Kaplan-Meier survival 
analysis, for single or combination therapy were: MTX, 28 months; HCQ, 18 months; 
LEF, 15 months; SSZ, 12 months. The study revealed that MTX monotherapy had longer 
persistence than MTX combination therapy (28 months vs.19 months; p = 0.001).
20
 
Similarly, Aletaha et al., in a survival analysis study with 42 months follow-up, 
demonstrated that MTX users had longer persistence (28 ± 1 months) than SSZ users (23 
± 1 months) or LEF users (20 ± 1 months).
21
 On the other hand, a Tennessee Medicaid 
prescription claims database study showed that using survival analysis, the overall 
persistence rates were similar among MTX, HCQ, LEF, and MTX + HCQ at 121-150 
days; however, SSZ was much lower at only 53 days during the 10 year study period.
75
 In 
another survival analysis, Grove et al. reported that <45% of MTX patients discontinued 
therapy at 96 months, while 50% of SSZ patients discontinued therapy at 34 months.
22
 
Furthermore, in a third survival analysis study with an average follow-up period of 13.6 ± 
9.3 years, high dose therapy was associated with a longer time to discontinuation of 
therapy (high dose MTX – 73 months vs. low dose MTX – 39 months; high dose SSZ – 
34 months vs. low dose SSZ – 7 months.23 Folate added to MTX resulted in longer 
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persistence compared to MTX alone (61.7 vs. 30.3 months). This study also used survival 
analysis to estimate the persistence rates.
82
 In a 10-year longitudinal prescription claims 
database study that investigated only MTX, of the total MTX index users (N=941), half 
of the patients had a treatment gap of over 90 days within 5 years of follow-up. On 
average, the patients experienced a 45 day treatment gap per year. The MTX treatment 
gap increased with older age, longer disease duration, low to moderate disease activity, 
and the presence of ulcer or mild liver disease.
83
 
In summary, previous studies have reported a wide range of adherence among 
non-biologic DMARDs. Only a few studies investigated individual non-biologic 
DMARD adherence rates. While the literature is scarce, two studies suggest that more 
frequent dosing and combination therapy may be associated with lower adherence.
70,75
 
Furthermore, being MTX users, taking high doses of medications (i.e., MTX, SSZ), being 
younger, having shorter disease duration, severe disease activity, and absence of ulcer or 
mild liver disease may have an association with longer medication persistence.
20-23,83
 
 
1.4.8 Initiation of biologic DMARDs  
Previous studies have shown that early initiation of non-biologic DMARDs or 
biologic DMARDs leads to long-term benefits during the disease course.
26,84,85
 Compared 
to non-biologic DMARDs, biologic DMARDs were shown to have better outcomes in 
radiographic structural joint damage, but not in disease activity.
86
 Currently, there are no 
established rules in the clinical practice guidelines that show when to initiate biologic 
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DMARDs. This section will focus on the current practice patterns and factors associated 
with the initiation of biologic DMARDs. 
1.4.8.1 Current practice patterns 
Variations exist across countries and individual practitioners regarding when to 
initiate biologic DMARDs. From a prescriber’s and patient’s point of view, the initiation 
of biologic DMARDs may vary because of their perceptions of drug efficacy, tolerability, 
and long-term safety, as well as reimbursement factors.
87
 
In a U.S. study that used commercial and Medicare databases, overall biologic 
DMARD use increased from 3% in 1999 to 26% in 2006. Among biologic DMARD 
initiators (N=8,218), 86% of patients received a non-biologic DMARD (66% were on 
MTX) 12 months prior, while 14% had no history of non-biologic DMARD use in the 
pre-period.
88
 In a Swedish study, Soderlin et al. reported that over 40% of biologic 
DMARD-naïve patients starting on biologic DMARDs had disease duration of less than 5 
years. Among these patients, those with disease duration of less than 2 years, the 
percentages of patients who initiated biologic DMARDs increased significantly from 3% 
in 1999 to 16% in 2006. As for the previous usage of non-biologic DMARD therapy, the 
percentages of biologic DMARD-naïve patients who previously used 1 or 2 consecutive 
non-biologic DMARDs increased, while those who used more than 2 consecutive non-
biologic DMARDs decreased during the years 1999 – 2006 (see Table 1.8). In addition, 
there was no trend in the percentages of these patients who were on previous DMARD 
combination therapy (ranges 23 – 34%). Compared to the previous U.S. study, this study 
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indicated a higher percentage (> 90%) of patients who had received MTX prior to 
biologic DMARD initiation. Furthermore, patients with shorter RA duration and less 
disease severity were shown to be treated increasingly with biologic DMARDs.
89
 In 
another Swedish study of RA patients, Zufferey et al. demonstrated that when biologic 
DMARDs were initiated earlier after RA diagnosis (5.5 years vs. other countries, 9 – 12 
years), the outcomes improved. These patients used fewer non-biologic DMARDs and 
they improved in disease activity score (DAS) and remission rates.
26
 
 
Table 1.8. Trend in the percentages of biologic DMARD-naïve patients starting on 
biologic DMARD who had previous non-biologic DMARD therapy
89
 
Non-biologic DMARD use 1999 2006 
1 previous  3% 27% 
2 consecutive  10% 19% 
>2 consecutive  56% 23% 
 
 
1.4.8.2 Factors associated with initiation of biologic DMARDs 
While there is currently no consensus regarding how early to start biologic 
DMARDs, there are various factors that may be associated with initiation of biologic 
DMARDs. As for socio-demographic factors, age, income, ethnicity/race, and insurance 
type may be related to initiation of biologic DMARDs, although there is no clinical 
reason for differential prescribing according to age or race/ethnicity.
24-26
 DeWitt et al. 
demonstrated that older individuals (each 10 year increase in the age; odds ratio [OR] = 
0.74, 95% CI = 0.66 – 0.82, p < 0.01) and lower annual income earners (each $10,000 
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reduction; OR = 0.95, 95% CI = 0.91 – 1.00, p = 0.04) were less likely to receive biologic 
DMARDs.
24
 Another study by Dewitt et al. found that although those on public insurance 
have more severe RA (i.e., higher disease severity, worse disability, and longer disease 
duration), those on private insurance tended to initiate biologic DMARDs earlier than 
those on public insurance.
90
 Furthermore, Pease et al. showed that there is variation 
among 13 countries in the initiation of anti-TNF agents, which may be because of 
different national reimbursement policies and different prescribing preferences. Five 
countries (i.e., Netherlands, Denmark, Norway, Sweden, U.S.), which have relatively less 
restrictive insurance policies for reimbursing biologic DMARDs, were shown to start 
biologic DMARDs at lower disease severity scores than others.
87
 
DeWitt et al. found that among clinical factors, disability and previous treatment 
with steroids or non-biologic DMARDs may be associated with initiating biologic 
DMARDs. While gender, race, employment status, comorbidity, previous NSAID use, 
and treatment center were not significant factors, disability (each 1-unit increase in the 
Health Assessment Questionnaire score; OR = 1.45, 95% CI = 1.22 – 1.72, p < 0.01 ) and 
previous treatment with steroids (OR = 2.24, 95% CI = 1.71 – 3.46, p < 0.01) or non-
biologic DMARDs (OR = 2.43, 95% CI = 1.71 – 3.46, p < 0.01) were significantly 
associated with initiation of biologic DMARDs.
24
 Even though the previous study 
showed no significant association between comorbidity and initiation of biologic 
DMARDs, it is important to note that there are some disease states (e.g., congestive heart 
failure, sepsis, tuberculosis) that require pretreatment before using biologic DMARDs or 
are contraindicated in certain biologic DMARDs. Thus some groups of patients would 
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not be recommended to use biologic DMARDs.
24,87
 Another factor that may predict 
initiation of biologic DMARDs is DAS. A review compared baseline characteristics of 
RA patients from twelve different countries’ databases at the time of initiation of anti-
TNF agents and noted that DAS ranged from 5.3 to 6.6 (high activity; see Table 1.3) at 
biologic DMARD initiation.
87,89,91
 Although there is currently no minimal DAS score at 
which biologic DMARDs are to be initiated, this evidence may suggest that the higher 
the DAS score, the higher likelihood of initiating biologic DMARDs.  
In summary, while there exist no established rules regarding when to initiate 
biologic DMARDs, previous studies showed that socio-demographic (age, income, 
ethnicity/race, and insurance type) and clinical (disability, RA severity, and previous 
therapy with steroids or non-biologic DMARDs) factors may be associated with the 
initiation of biologic DMARDs.
24-26
  
 
1.4.9 Texas Medicaid and biologic DMARD utilization management 
The Medicaid program is a jointly managed health care program by federal and 
state government that is intended to provide low-income Americans with access to health 
care. The Medicaid program was established in 1965 by Congress under Title XIX of the 
Social Security Act. The Texas Medicaid program began in September 1967. As years 
passed, Congress expanded the Medicaid eligible population to those with disabilities, 
children, pregnant women and older individuals. While the Social Security Act and 
federal regulations set the minimum requirements for health care coverage that state 
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Medicaid programs have to provide, each state develops its own health care program by 
including optional services and eligibility groups. Medicaid pays for acute health care as 
well as long-term care services. There are currently over 3.6 million Texas residents who 
are enrolled in Medicaid each month. As of the state fiscal year 2011, 55% of the 
Medicaid beneficiaries were female, and 77% were under 21 years old. Although the 
majority of recipients are non-disabled children (66%), they comprised only 33% of 
Texas Medicaid direct health care expenditures. Whereas, the elderly, blind, or disabled 
(25% of the Texas Medicaid population) comprised 58% of the expenditures.
92
  
As Medicaid faces budget constraints, managing utilization of costly medications 
such as biologic DMARDs is a major concern. Fischer et al. showed that between 1999 
and 2005, 32 states implemented or planned to implement prior authorization for 
Medicaid, with a wide variation of criteria, as a cost containment strategy. Texas had not 
implemented nor planned to implement the strategy. Despite the effort, biologic DMARD 
use was low only at the beginning of introducing prior authorization; total expenditures 
of state Medicaid programs on DMARDs increased dramatically from $200 million in 
1999 to $567 million in 2005. Whereas $27.7 million (13.8% of expenditure on 
DMARDs) was spent on etanercept in 1999, $255 million (44.8%) was spent on 
etanercept and adalimumab. 
93
 As of 2013, Texas Medicaid has a preferred drug list of 
etanercept and adalimumab for the biologic DMARD class and prior authorization 
criteria is as follows: (1) treatment failure with preferred drugs within any subclass; (2) 
contraindication to preferred drugs; (3) allergic reaction to preferred drugs. 
94
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1.4.10 Study purpose 
Medication adherence and persistence are important for optimal RA management. 
From the payer’s perspective, medication utilization patterns may be related to health 
care costs and outcomes. Because of their significant cost, it is important to understand 
more about initiation of biologic DMARDs, other RA medication utilization patterns, as 
well as factors associated with initiation of biologic DMARDs. Addressing this gap in the 
literature, this retrospective database study of Texas Medicaid recipients may be 
meaningful for the following reasons: (1) understanding drug utilization patterns and 
factors associated with the initiation of biologic DMARDs in an underserved and diverse 
population and (2) evaluating drug utilization and management of biologic DMARD use 
in patients with RA. 
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1.4.11 Study objectives and hypotheses 
1. Describe patient socio-demographic (age, gender, race), medication use patterns 
[non-biologic DMARD type, non-biologic DMARD therapy (i.e., monotherapy, 
dual therapy), non-biologic DMARD adherence and persistence, pain medication 
use, glucocorticoid use], and clinical characteristics (i.e., comorbidities, and 
rheumatologist visit). 
  
2. To determine whether adherence and persistence differ by non-biologic DMARD 
type. 
H2a Adherence to methotrexate is significantly higher than adherence to other 
non-biologic DMARD types. 
H2b Persistence to methotrexate is significantly higher than persistence to other 
non-biologic DMARD types. 
 
3. To determine whether adherence and persistence differ by non-biologic DMARD 
therapy. 
H3a Adherence to non-biologic DMARD monotherapy is significantly higher 
than adherence to non-biologic DMARD dual therapy. 
H3b Persistence to non-biologic DMARD monotherapy is significantly higher 
than persistence to non-biologic DMARD dual therapy. 
 
4. To determine whether time to initiation of biologic DMARDs differs by non-
biologic DMARD type and therapy. 
H4a Time to initiation of biologic DMARDs does not differ significantly by non-
biologic DMARD type. 
H4b Time to initiation of biologic DMARDs does not differ significantly by non-
biologic DMARD therapy. 
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5. To determine if the likelihood of patients initiating biologic DMARDs differs by 
non-biologic DMARD type and therapy, while controlling for covariates: patient 
socio-demographics (age, gender, race), medication use patterns (non-biologic 
DMARD adherence and persistence, pain medication use, glucocorticoid use), 
and clinical characteristics (i.e., comorbidities, and rheumatologist visit). 
H5a The likelihood of methotrexate users initiating biologic DMARDs is 
significantly higher than that of methotrexate non-users, while controlling 
for covariates. 
H5b The likelihood of non-biologic DMARD dual therapy users initiating 
biologic DMARDs is significantly higher than that of non-biologic 
DMARD monotherapy users, while controlling for covariates. 
H5c With every year increase in age, the likelihood of patients initiating biologic 
DMARDs decreases significantly, while controlling for covariates.   
H5d Females are significantly more likely to initiate biologics compared to 
males, while controlling for covariates.   
H5e Caucasians are significantly more likely to initiate biologic DMARDs 
compared to non-Caucasians, while controlling for covariates.  
H5f Non-adherent (PDC < 70%) patients are significantly more likely to initiate 
biologic DMARDs compared to adherent patients, while controlling for 
covariates. 
H5g With every day decrease in persistence, the likelihood of initiating biologic 
DMARDs increases significantly, while controlling for covariates. 
H5h Pain medication users are significantly more likely to initiate biologic 
DMARDs compared to pain medication non-users, while controlling for 
covariates.  
H5i Glucocorticoid non-users are significantly more likely to initiate biologic 
DMARDs compared to glucocorticoid users, while controlling for 
covariates.   
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H5j With every unit increase in the Charlson Comorbidity Index score, the 
likelihood of initiating biologic DMARDs increases, while controlling for 
covariates.  
H5k Patients seen by rheumatologists are significantly more likely to initiate 
biologic DMARDs compared to patients seen by non-rheumatologists, while 
controlling for covariates.   
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Chapter 2: Methodology 
2.1 CHAPTER OVERVIEW 
In this chapter, the study methods will be described in detail. The following will 
be presented: study design (e.g., inclusion and exclusion criteria, study periods), data 
source (e.g., data extraction method, study population). The operational definitions of 
each study variable and statistical analytical method will be described. In addition, 
sample sizes will be presented for study objectives.      
2.2 INSTITUTIONAL REVIEW BOARD APPROVAL 
The study was reviewed by the Institutional Review Board of The University of 
Texas at Austin. The Board determined that IRB oversight was not necessary because the 
data were de-identified; thus, the study did not meet requirements for human subjects 
research. 
2.3 STUDY DESIGN AND DATA SOURCE 
This is a retrospective study using Texas Medicaid prescription and medical 
claims data during the study period of July 1, 2003 – December 31, 2010. The study 
subjects were adult (18 – 63 years) patients diagnosed with RA. The following 
subsections will explain the inclusion and exclusion criteria, study periods, and methods 
for data collection.  
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2.3.1 Inclusion and exclusion criteria 
Inclusion criteria: 
Texas Medicaid recipients who meet the following criteria were included: 
1) Between the ages 18 – 63 years at the index date; 
2) Continuously enrolled for at least 6 months before and 24 months after the 
index date; 
3) Diagnosed with RA during the pre-index period (International Classification 
of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 714.xx); 
4) No non-biologic DMARD used during the pre-index period; 
5) No biologic DMARD used during the pre-index period; 
6) At least 2 of the same non-biologic DMARDs in the post-index period.  
 
Exclusion criteria: 
Patients diagnosed with other types of arthritic or autoimmune disorders such as: 
psoriasis (ICD-9-CM 696.0x), psoriatic arthritis (ICD-9-CM 696.1x or 696.8x), 
ankylosing spondylitis (ICD-9-CM 720.0x), ulcerative colitis (ICD-9-CM 556.9), or 
Crohn’s diseases (ICD-9-CM 555.0x, 555.1x, 555.2x, 555.9x, 565.1x, or 569.81) during 
the entire study period were excluded because biologic DMARDs are indicated for 
treatment with these disorders. In addition, patients with comorbid disorders such as 
leukemia (ICD-9-CM 208.x), non-Hodgkin’s lymphoma (ICD-9-CM 202.8x), head, neck, 
lung, and breast cancers (ICD-9-CM 171.0, 162.9, 174.9), osteosarcoma (ICD-9-CM 
170.9), mycosis fungoides (ICD-9-CM 202.1), gestational trophoblastic neoplasm (ICD-
9-CM 181), lupus erythematosus (ICD-9-CM 710.0), malaria (ICD-9-CM 084.6), 
collagen disease (ICD-9-CM 710.9), exacerbation of multiple sclerosis (ICD-9-CM 340), 
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idiopathic thrombocytopenic purpura (ICD-9-CM 287.3), neoplastic disease (ICD-9-CM 
239.9), nephritis disease/syndrome (ICD-9-CM 581), polymyositis (ICD-9-CM 710.4), 
renal transplant rejection (ICD-9-CM 996.81), transplantation of heart (ICD-9-CM 
V42.1), trichinosis (ICD-9-CM 124), tuberculosis meningitis (ICD-9-CM 013.0) during 
the study period were excluded because these disorders are also treated with non-biologic 
DMARDs or glucocorticoids.
19
   
2.3.2 Index date  
The index date was the date of the first prescription claim for a non-biologic 
DMARD agent. 
2.3.3 Data collection and study periods 
The following data were obtained from the Texas Medicaid medical and 
prescription claims database: de-identified patient identification numbers, gender, age, 
race/ethnicity, enrollment dates, diagnostic codes (i.e., ICD-9-CM codes), National Drug 
Codes (NDCs), prescription fill date, outpatient procedure codes for injectables, days 
supply, and prescriber type.  
Data collection period 
 
July 1, 2003         January 1, 2004                    December 31, 2008       December 31, 2010 
 
 
 
Pre-index period              Index period         Post-index period  
   
 Index date 
= 1
st 
non-biologic 
DMARD use 
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2.4  STUDY VARIABLES  
Table 2.1 below describes operational definitions of each study variable.  
2.4.1 Dependent variables 
The primary dependent variables for this study were time to initiation of biologic 
DMARDs and likelihood of initiating biologic DMARDs. The secondary dependent 
variables included medication adherence and persistence. Note: the secondary dependent 
variables also serve as covariates in objective 5. 
2.4.2  Independent variables (and covariates) 
The primary independent variables were non-biologic DMARD type and non-
biologic DMARD therapy. The study covariates were: (1) clinical factors (adherence and 
persistence to non-biologic DMARDs, comorbid conditions, pain medication use, 
glucocorticoid use, rheumatologist visit); and (2) socio-demographic factors (age, gender, 
race). 
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Table 2.1. Operational definitions of study variables 
Study variables Operational definitions 
Dependent variables 
Time to initiation of 
biologic DMARDs 
The number of days between the index date and the first 
biologic DMARD (i.e., abatacept, rituximab, tocilizumab, 
adalimumab, etanercept, infliximab, certolizumab, golimumab) 
fill date  
[continuous variable] 
Initiation of biologic 
DMARDs 
1 = Yes, 0 = No 
[dichotomous variable] 
Medication adherence Measured using PDC (proportion of days covered) to non-
biologic DMARDs during the post-index period.  
PDC=Number of days when drugs were available x 100 / 
number of days in the study period 
[continuous variable] 
1 = ≥ 70% PDC, 0=<70% PDC  
[categorical] 
(Note: Covariate for Objective 5)  
Medication persistence
a 
The number of days in which non-biologic DMARD was 
continuously used during the post-index period without a gap.  
Gap period: last days supply + 60 days (sensitivity analyses: 
last days supply + 45 days; last days supply + 90 days).  
[continuous variable] 
(Note: Covariate for Objective 5) 
Independent variables 
Non-biologic DMARD type 1 = methotrexate, 2 = sulfasalazine, 3 = hydroxychloroquine,  
4 = leflunomide 
[categorical variable] 
Non-biologic DMARD 
therapy
b 
1 = monotherapy, 2 = dual therapy 
[categorical variable] 
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Table 2.1. Operational definitions of study variables, cont.  
Covariates  
Clinical factors 
Comorbid conditions Charlson Comorbidity Index score were derived from the sum 
of relevant weighted conditions. See Table 2.2 for algorithm 
1 = score of 1, 2 = score of 2, 3 = score of ≥3 
[ordinal variable] 
Pain medication use 1 = Yes, 0 = No 
[categorical variable]  
Glucocorticoid use during 
the post-index period 
1 = Yes, 0 = No 
[categorical variable] 
 
Rheumatologist visit 
 
Rheumatologist visit during study period 
1 = Yes, 0 = No 
[categorical variable] 
Socio-demographic factors 
Age Age of the subject at index date  
[continuous variable] 
Gender 0 = Male, 1 = Female  
[categorical variable] 
Race
c 
1 = Caucasian, 2 = African American, 3 = Hispanic, 4 = Others 
[categorical variable] 
DMARD, disease-modifying antirheumatic drug; NSAID, nonselective nonsteroidal anti-inflammatory 
drugs 
a
 Persistence gap period of last days supply + 60 days was selected because 2 months without treatment is a 
reasonable period to assume that the patient has discontinued therapy.  
b 
Dual therapy was defined as the two non-biologic DMARDs filled with two overlapping  
periods of at least 15 days, with the first claim filled within 4 months of the index date. 
c 
Others included American Indians, Asians, and unknown. 
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Table 2.2. Charlson comorbidity index scoring algorithm 
Comorbid 
Conditions 
Weights Dartmouth-Manitoba codes 
Myocardial 
infarction 
1 410.xx, 412* 
Congestive heart 
failure 
1 402.01, 402.11, 402.91, 425.x, 428.x, 429.3, 404.01, 
404.03, 404.11, 404.13, 404.91, 404.93 
Peripheral vascular 
disease 
1 440.x*, 441.x*, 442.x*, 443.1-443.9*, 447.1*, 785.4*, 
38.13-38.14(P)*, 38.16(P)*, 38.18(P)*, 38.33-
38.34(P)*, 38.36(P)*, 38.38(P)*, 38.43-38.44(P)*, 
38.46(P)*, 38.48(P)*, 39.22-39.26(P)* 
Cerebrovascular 
disease 
1 362.34, 430-436, 437-437.1, 437.9, 438, 781.4, 784.3, 
997.0, 38.12(P), 38.42(P) 
Dementia 1 290.x*, 331-331.2* 
Chronic pulmonary 
disease 
1 415.0*, 416.8-416.9*, 491.x-494*, 496* 
Connective tissue 
disease 
1 710.x, 714.x 
Ulcer disease 1 531.xx-534.xx 
Mild liver disease 1 571.2*, 571.5-571.6*, 571.8-571.9* 
Diabetes 1 250.0x-250.3x* 
Diabetes  with end 
organ damage 
 250.4x-250.9x*† 
Hemiplegia 2 342.x, 344.x 
Moderate or severe 
renal disease 
2 585-586*, V42.0*, V45.1*, V56.x*, 39.27(P)*, 
39.42(P)*, 39.93-39.95(P)*, 54.98(P)* 
Any tumor 2 140.x-171.x*, 174.x-195.x*, 200.xx-208.x*, 273.0*, 
273.3*, V10.46*, 60.5(P)*, 62.4-62.41(P) Leukemia 2 
Lymphoma 2 
Moderate or severe 
liver disease 
3 572.2-572.4*, 456.0-456.2x*, 39.1(P)*, 42.91(P)*† 
Metastatic solid 
tumor 
6 196.x-199.x*† 
AIDS 6 042.x-044.x 
(P) follows all ICD-9-CM codes that describe procedures rather than diagnoses (Vol.III). 
* The codes with asterisks are included in the definition of a comorbidity if they are listed during either 
index or prior hospital discharges; other codes are included only if recorded prior to the index discharge. 
Each asterisk applies to all codes within the indicated range. 
†In the Dartmouth-Manitoba algorithm, these comorbidities take precedence over less severe comorbidities 
involving the same organ system. 
Source : Adapted from:Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with 
ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46(10):1075-1079; 
discussion 1081-1090. 
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2.5  STATISTICAL ANALYSIS AND SAMPLE SIZE 
In performing data analysis, SAS for Windows, Version 9.3 (SAS Institute, Cary, 
NC.) was used. For all statistical analyses, tests were two-tailed and the significance level 
was determined at probability (p) < 0.05. Data distributions were evaluated by 
performing frequencies, histograms, and box plots. To address study objective 1, 
descriptive statistics were performed. For objectives 2 and 3, data distributions were 
inspected for normality, and appropriate parametric (i.e., ANOVA, t-test) or non-
parametric (i.e., Kruskal Wallis, Mann-Whitney U) tests were used accordingly. 
Statistical tests for each study hypothesis are shown in Table 2.3. Kaplan-Meier analysis 
and logistic regression analysis were used for objectives 4 and 5, respectively.  
2.5.1 Statistical test assumptions and sample size calculations  
This section will present the statistical test assumptions and sample size 
calculations for each study objective.  
Analysis of Variance (ANOVA)  
To address study objective 2, one-way ANOVA was employed because both of 
measurement variables (i.e., adherence, persistence) were normally distributed. In each 
ANOVA test, there was a set of one measurement variable and one nominal variable (i.e., 
non-biologic DMARD type). There were three basic assumptions: independent 
observations, normal distribution of data, and homogeneity of variances.  
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For ANOVA, the total sample size was calculated using G-Power software and 
resulted in 100 subjects (medium effect size (f) = 0.36, α = 0.05, power = 0.8, number of 
groups = 5) for objective 2. The total sample size needed for objective 3 was 92 based on 
G-Power software (medium effect size (f) = 0.36, α = 0.05, power = 0.8, number of 
groups = 4).  
T-test and Mann-Whitney U test 
To address study objective 3, t-tests were used because the measurement variables 
(e.g., adherence, persistence) were normally distributed. In t-test, two groups (i.e., non-
biologic DMARD therapy) were compared. There were three assumptions: independent 
observations, normal distribution of data, and homogeneity of variances.  
Chi-square test 
For objectives 2 and 3, after performing ANOVA and t-test, a chi-square test was 
further performed to compare the proportions of adherence (PDC ≥ 70%) in each 
dichotomous variable (i.e., methotrexate users vs. non-methotrexate users; monotherapy 
users vs. dual therapy users) (see Tables 2.3 and 2.4). Because the literature lacks 
information on the proportions of adherence, the tables below show comparisons of 
various percentages representing possible proportions of adherence comparisons. Thus 
the needed sample size ranged between 80 and 137. 
 
 
  52 
Table 2.3. Sample sizes needed for chi-square test depending on varying 
proportions of adherence in methotrexate users vs. non-methotrexate 
users 
Proportion of 
adherence
a
 in 
methotrexate 
users 
Proportion of 
adherence
a
 in non-
methotrexate users 
Sample Size 
25% 10% 97 
30% 15% 118 
35% 20% 137 
40% 20% 80 
a 
Adherence is defined as proportion of days covered (PDC) ≥ 70% 
Table 2.4. Sample sizes needed for chi-square test depending on varying proportions 
of adherence in non-biologic DMARD monotherapy users vs. non-
biologic DMARD dual therapy users 
Proportion of 
adherence
a
 in 
non-biologic 
DMARD 
monotherapy 
users 
Proportion of 
adherence
a
 in non-
biologic DMARD 
dual therapy users 
Sample Size 
80% 60% 80 
70% 50% 92 
60% 40% 97 
a 
Adherence is defined as proportion of days covered (PDC) ≥ 70% 
 
Kaplan-Meier analysis and log rank test 
Kaplan-Meier analysis was used to estimate the fraction of study subjects 
reaching the study endpoint (i.e., time to initiation of biologic DMARDs) as addressed in 
objective 4. The time frame was from the time when subjects started on a non-biologic 
DMARD to the time when they started on a biologic DMARD. Survival function curves 
of time to initiation to biologic DMARD were plotted by the measurement variable (i.e., 
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non-biologic DMARD type and therapy). Log rank test was used to further test whether 
there is a significant difference between the survival times of different treatment groups.  
 
Logistic regression analysis 
Logistic regression was performed to address objective 5. Logistic regression was 
used because the dependent variable (i.e., initiation of biologic DMARDs) is binary (i.e., 
yes or no). The following is the logistic regression model: 
ln [π(x)/(1-π(x))] = β0 + β1x1 + β2x2 + β3x3 + β4x4 + β5x5 + β6x6 + β7x7+ β8x8 + β9x9 + 
β10x10 + β11x11 
π(x) = probability of initiating biologic DMARDs 
1-π(x) = probability of not initiating biologic DMARDs 
β0 = constant = intercept of the logistic regression model 
βn = regression coefficient 
x1 = non-biologic DMARD type 
x2 = non-biologic DMARD therapy 
x3 = medication adherence 
x4 = medication persistence 
x5= Charlson comorbidity score 
x6= pain medication use 
x7= glucocorticoid use 
x8= age 
x9= gender 
x10= race 
x11= rheumatologist visit 
 
As for sample size calculation, G-Power showed that a total of 1,138 patients 
would be needed to address this objective (odds ratio = 1.2, Pr (Y=1/X=1) H0 = 0.3, α = 
0.05, power = 0.8). Since this analysis requires the largest sample size for the study, 
1,138 was selected to perform data analysis.  
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Table 2.5.  Summary of study objectives/hypotheses, study variables, study 
measures, and statistical tests 
Objectives/ 
hypotheses 
Dependent 
variable 
Measurement 
level 
Independent 
variable 
Measurement level Statistical 
analysis 
Objective 1: 
Describe patient socio-demographic (age, gender, race), medication use patterns [non-biologic DMARD type, non-
biologic DMARD therapy (i.e., monotherapy, dual therapy), non-biologic DMARD adherence and persistence, 
pain medication use, glucocorticoid use], and clinical characteristics (i.e., comorbidities and rheumatologist visit). 
   Age Continuous Mean (SD) 
  Gender Categorical 
0 = Male 
1 = Female  
Frequencies 
  Race Categorical 
1 = Caucasian 
2 = African American  
3 = Hispanic 
4 = Others 
Frequencies 
  Non-biologic 
DMARD type 
Categorical 
1 = methotrexate 
2 = sulfasalazine 
3 = hydroxychloroquine 
4 = leflunomide 
 
Frequencies 
  Non-biologic 
DMARD therapy 
Categorical 
1 = monotherapy 
2 = dual therapy 
 
Frequencies 
Non-biologic 
DMARD 
adherence 
Continuous 
Categorical 
0 = nonadherent 
(<70% PDC) 
1 = adherent  
(≥70% PDC) 
  Mean (SD) 
 
Frequencies 
Non-biologic 
DMARD 
persistence 
Continuous   Mean (SD) 
 
  pain medication 
use 
Categorical 
1 = yes 
0 = no 
Frequencies  
  Glucocorticoid use Categorical 
1 = yes 
0 = no 
Frequencies 
  Comorbidities Ordinal 
1= score of 1 
2= score of 2 
3= score of ≥3 
Frequencies 
 
  Rheumatologist 
visit 
 
Categorical 
1 = Yes 
0 = No 
Frequencies 
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Table 2.5. Summary of study objectives/hypotheses, study variables, study 
measures, and statistical tests, cont. 
 
Objectives/ 
hypotheses 
Dependent 
variable 
Measurement 
level 
Independent 
variable 
Measurement level Statistical 
analysis 
Objective 2: 
To determine whether adherence and persistence differ by non-biologic DMARD type. 
H2a: Adherence to methotrexate is significantly higher than adherence to other non-biologic DMARD types 
 Adherence 
 
Continuous 
 
 
Non-biologic 
DMARD type 
Categorical 
1 = methotrexate 
2 = sulfasalazine 
3 = hydroxychloroquine 
4 = leflunomide 
 
ANOVA or 
Kruskal 
Wallis 
 
 Adherence  
 
Categorical 
0 = nonadherent 
(<70% PDC) 
1 = adherent  
(≥70% PDC) 
 
Non-biologic 
DMARD type 
Categorical 
1 = methotrexate 
2 = sulfasalazine 
3 = hydroxychloroquine 
4 = leflunomide 
 
Chi-square 
H2b: Persistence to methotrexate is significantly higher than persistence to other non-biologic DMARD types 
  Continuous Non-biologic 
DMARD type 
Categorical 
1 = methotrexate 
2 = sulfasalazine 
3 = hydroxychloroquine 
4 = leflunomide 
 
ANOVA or 
Kruskal 
Wallis 
Objective 3: 
To determine whether adherence and persistence differ by non-biologic DMARD therapy. 
H3a: Adherence to non-biologic DMARD monotherapy is significantly higher than adherence to non-biologic DMARD 
dual therapy. 
 Adherence  
 
 
 
 
Continuous 
 
 
 
 
Non-biologic 
DMARD therapy 
Categorical 
1 = monotherapy 
2 = dual therapy 
 
t-test 
 
 
 Adherence  
 
Categorical 
0 = nonadherent 
(<70% PDC) 
1 = adherent  
(≥70% PDC) 
Non-biologic 
DMARD therapy 
Categorical 
1 = monotherapy 
2 = dual therapy 
 
Chi-square 
H3b: Persistence to non-biologic DMARD monotherapy is significantly higher than persistence to non-biologic DMARD 
dual therapy. 
 Persistence Continuous Non-biologic 
DMARD therapy 
Categorical 
1 = monotherapy 
2 = dual therapy 
 
t-test 
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Table 2.5. Summary of study objectives/hypotheses, study variables, study 
measures, and statistical tests, cont. 
 
Objectives/ 
hypotheses 
Dependent 
variable 
Measurement 
level 
Independent 
variable 
Measurement level Statistical 
analysis 
Objective 4: 
To determine whether time to initiation of biologic DMARDs differs by non-biologic DMARD type and therapy. 
H4a: Time to initiation of biologic DMARDs does not differ significantly by non-biologic DMARD type. 
 Time to 
initiation of 
biologic 
DMARDs 
Continuous Non-biologic 
DMARD type 
Categorical 
1 = methotrexate 
2 = sulfasalazine 
3 = hydroxychloroquine 
4 = leflunomide 
 
Kaplan-Meier 
analysis 
 
Log-rank test 
H4b: Time to initiation of biologic DMARDs does not differ significantly by non-biologic DMARD therapy. 
 Time to 
initiation of 
biologic 
DMARDs 
Continuous Non-biologic 
DMARD therapy 
Categorical 
1 = monotherapy 
2 = dual therapy 
 
Kaplan-Meier 
analysis 
 
Log-rank test 
Objective 5: 
To determine if the likelihood of patients initiating biologic DMARDs differs by non-biologic DMARD type and 
therapy, while controlling for covariates: patient socio-demographics (age, gender, race), medication use patterns 
(i.e., non-biologic DMARD adherence and persistence, pain medication use, glucocorticoid use), and clinical 
characteristics (i.e., comorbidities, and rheumatologist visit). 
H5a: The likelihood of methotrexate users initiating biologic DMARDs is significantly higher than that of methotrexate 
non-users, while controlling for covariates. 
 Initiation of 
biologic 
DMARDs  
Categorical  
1 = yes 
0 = no 
Non-biologic 
DMARD type 
 
Categorical 
1 = methotrexate 
2 = sulfasalazine 
3 = hydroxychloroquine 
4 = leflunomide 
 
Logistic 
regression 
analysis 
H5b: The likelihood of non-biologic DMARD dual therapy users initiating biologic DMARDs is significantly higher than 
that of non-biologic DMARD monotherapy users, while controlling for covariates. 
 Initiation of 
biologic 
DMARDs  
Categorical  
1 = yes 
0 = no 
Non-biologic 
DMARD therapy 
Categorical 
1 = monotherapy 
2 = dual therapy 
 
Logistic 
regression 
analysis 
H5c: With every year increase in age, the likelihood of patients initiating biologic DMARDs decreases significantly, 
while controlling for covariates.   
 Initiation of 
biologic 
DMARDs  
Categorical  
1 = yes 
0 = no 
Age 
 
Continuous 
 
 
Logistic 
regression 
analysis 
H5d: Females are significantly more likely to initiate biologics compared to males, while controlling for covariates. 
 Initiation of 
biologic 
DMARDs 
Categorical 
1 = yes 
0 = no 
Gender 
 
 
Categorical 
0 = male 
1 = female 
Logistic 
regression 
analysis 
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Table 2.5. Summary of study objectives/hypotheses, study variables, study 
measures, and statistical tests, cont. 
Objectives/ 
hypotheses 
Dependent 
variable 
Measurement 
level 
Independent 
variable 
Measurement level Statistical 
analysis 
H5e: Caucasians are significantly more likely to initiate biologic DMARDs compared to non-Caucasians, while 
controlling for covariates. 
 Initiation of 
biologic 
DMARDs 
Categorical 
1 = yes 
0 = no 
Race Categorical 
1 = Caucasian 
2 = African American 
3 = Hispanic 
4 = Others 
Logistic 
regression 
analysis 
H5f: Non-adherent (PDC < 70%) patients are significantly more likely to initiate biologic DMARDs compared to 
adherent patients, while controlling for covariates. 
 Initiation of 
biologic 
DMARDs 
Categorical 
1 = yes 
0 = no 
Adherence  
 
 
 
 
Categorical 
0 = nonadherent 
(<70% PDC) 
1 = adherent  
(≥70% PDC) 
Logistic 
regression 
analysis 
H5g: With every day decrease in persistence, the likelihood of initiating biologic DMARDs increases significantly, while 
controlling for covariates. 
 Initiation of 
biologic 
DMARDs 
Categorical 
1 = yes 
0 = no 
Persistence 
 
 
Continuous 
 
Logistic 
regression 
analysis 
H5h: Pain medication users are significantly more likely to initiate biologic DMARDs compared to pain medication non-
users, while controlling for covariates. 
 Initiation of 
biologic 
DMARDs 
Categorical 
1 = yes 
0 = no 
Pain medication 
use 
 
Categorical 
1 = yes 
0 = no 
Logistic 
regression 
analysis 
H5i: Glucocorticoid non-users are significantly more likely to initiate biologic DMARDs compared to glucocorticoid 
users, while controlling for covariates.   
 Initiation of 
biologic 
DMARDs 
Categorical 
1 = yes 
0 = no 
Glucocorticoid use 
 
Categorical 
1 = yes 
0 = no 
Logistic 
regression 
analysis 
H5j: With every unit increase in the Charlson Comorbidity Index score, the likelihood of initiating biologic DMARDs 
increases, while controlling for covariates. 
 Initiation of 
biologic 
DMARDs 
Categorical 
1 = yes 
0 = no 
Charlson 
Comorbidity Index 
score 
Ordinal 
1= score of 1 
2= score of 2 
3= score of ≥3 
Logistic 
regression 
analysis 
H5k: Patients seen by rheumatologists will be significantly more likely to initiate biologic DMARDs 
compared to patients seen by non-rheumatologists, while controlling for covariates.   
 Initiation of 
biologic 
DMARDs 
Categorical Rheumatologist 
visit 
 
Categorical 
1 = Rheumatologist 
2 = non-
rheumatologist 
Logistic 
regression 
analysis 
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Chapter 3: Results 
3.1  CHAPTER OVERVIEW 
This chapter describes the study results. First, the extraction process of eligible 
subjects from the database will be presented. Then patients’ baseline demographic and 
clinical characteristics will follow. The rest of chapter will present the results of the study 
objectives. 
3.2 FINAL SAMPLE  
The initial population was comprised of 30,464 Texas Medicaid recipients with a 
diagnosis of RA during the study period. Of these, 20,521 subjects (67.4%) did not have 
any prescriptions for non-biologic DMARDs during the identification period, resulting in 
a sample size of 9,943 subjects. After applying the remaining criteria, 2,714 subjects 
comprised as the final study sample (Table 3.1). 
  
  59 
Table 3.1. Attrition of study subjects in Texas Medicaid database  
Criteria Subjects 
Excluded 
Subjects 
Remaining 
N % N % 
Initial  Sample 30,464 100.0 
Had any non-biologic DMARD during the identification period
a
 20,521 67.4 9,943 32.6 
Had at least 2 of the same index non-biologic DMARDs during the 
postindex period
b
 
1,699 5.6 8,244 27.1 
No use of non-biologic or biologic DMARD during the preindex 
period
c 
2,267 7.4 5,977 19.6 
Age 18-63 years on index date 318 1.0 5,659 18.6 
Had no disorders from the exclusion criteria during the study period
d 
838 2.7 4,821 15.8 
Met the continuous eligibility criteria 2,090 6.9 2,731 9.0 
Non-biologic monotherapy or dual therapy users only 17 0.0 2,714 8.9 
Final sample 2,714  
 DMARD = disease-modifying antirheumatic drug; RA = rheumatoid arthritis   
 a July 1, 2003 to December 31, 2008 
  b January 1, 2004 to December 31, 2010 
  c July 1, 2003 to December 31, 2003 
d Other types of arthritic or autoimmune disorders such as: psoriasis (ICD-9-CM 696.0x), psoriatic arthritis (ICD-9-
CM 696.1x or 696.8x), ankylosing spondylitis (ICD-9-CM 720.0x), ulcerative colitis (ICD-9-CM 556.9) or 
Crohn’s diseases (ICD-9-CM 555.0x, 555.1x, 555.2x, 555.9x, 565.1x, or 569.81); leukemia (ICD-9-CM 208.x), 
non-Hodgkin’s lymphoma (ICD-9-CM 202.8x), head, neck, lung, and breast cancers (ICD-9-CM 171.0, 162.9, 
174.9), osteosarcoma (ICD-9-CM 170.9), mycosis fungoides (ICD-9-CM 202.1), gestational trophoblastic 
neoplasm (ICD-9-CM 181), lupus erythematosus (ICD-9-CM 710.0), malaria (ICD-9-CM 084.6), collagen disease 
(ICD-9-CM 710.9), exacerbation of multiple sclerosis (ICD-9-CM 340), idiopathic thrombocytopenic purpura 
(ICD-9-CM 287.3), neoplastic disease (ICD-9-CM 239.9), nephritis disease/syndrome (ICD-9-CM 581), 
polymyositis (ICD-9-CM 710.4), renal transplant rejection (ICD-9-CM 996.81), transplantation of heart (ICD-9-
CM V42.1), trichinosis (ICD-9-CM 124), tuberculosis meningitis (ICD-9-CM 013.0)  
 
3.3 STUDY OBJECTIVES 
3.3.1  Objective 1: Description of baseline demographic and clinical characteristics 
Objective 1 was to describe patient socio-demographic (age, gender, race), 
medication use patterns [i.e., non-biologic DMARD type, non-biologic DMARD therapy 
(i.e., monotherapy, dual therapy)], non-biologic DMARD adherence and persistence, pain 
medication use, glucocorticoid use, and clinical characteristics (i.e., comorbidities and 
rheumatologist visit). Baseline demographic and clinical characteristics of the final 
sample are shown in Table 3.2. 
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3.3.1.1 Demographic characteristics  
The majority of the subjects were 45 – 63 years of age (68.8%) with mean(±SD) 
age of 48.1(±10.4) years. The subjects were predominantly female (89.1%) and Hispanic 
(55.3%). 
3.3.1.2 Medication use and clinical characteristics 
With respect to non-biologic DMARD type, almost 45 percent (44.8%) of 
subjects were prescribed MTX, followed by HCQ (25.1%). Over 10 percent (13.6%) 
were dual therapy users. The majority of subjects were monotherapy non-biologic 
DMARD users (86.4%). Mean PDC adherence for non-biologic DMARDs was 
30.6%(±25.2%). Regarding dichotomous adherence, the initial cut-off value was 80%. 
However, it resulted in invalid tests because of small cell sizes. Thus, the PDC cut-off 
value was changed to 70%. The vast majority (89.9%) of subjects were non-adherent 
(PDC<70%) and their mean persistence was 190.2(±201.4) days. Regarding other 
medication use, most subjects shifted from glucocorticoid non-users (69.8%) in the pre-
index period to glucocorticoid users (64.9%) in the post-index period. Over 90 percent 
(92.4%) of the sample were on pain medications in the post-index period. The majority of 
subjects had either a Charlson Comorbidity Index (CCI) score of 1 (58.9%) or 2 (28.9%). 
Finally, over 70 percent (73.9%) of subjects were prescribed a non-biologic DMARD by 
a non-rheumatologist. Note: Less than 5% (3.8%) of subjects were missing data on 
prescriber type. 
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Table 3.2. Baseline descriptive statistics  
Demographic Characteristics N %
a
 
Age groups 
18-34 334 12.3 
35-44 512 18.9 
45-54 939 34.6 
55-63 929 34.2 
Total 2,714 100.0 
Mean(±SD) 48.1(±10.4) 
Race/ethnicity
∞ 
 Caucasians 630 23.2 
 African Americans 286 10.5 
 Hispanics 1,500 55.3 
 Others 298 11.0 
 Total 2,714 100.0 
Gender 
Females 2,418 89.1 
Males 296 10.9 
  Total 2,714 100.0 
 
Medication Use and Clinical Characteristics N %
a
 
Non-biologic DMARD type (index drug) 
MTX 1,216 44.8 
SSZ 360 13.3 
HCQ 682 25.1 
LEF 86 3.2 
Dual therapy (MTX+SSZ, MTX+HCQ, 
MTX+LEF) 
370 13.6 
  Total 2,714 100.0 
Non-biologic DMARD therapy 
Monotherapy 2,344 86.4 
Dual therapy 370 13.6 
Total 2,714 100.0 
Adherence to non-biologic DMARDs 
Yes (PDC ≥ 70%) 275 10.1 
No (PDC < 70%) 2,439 89.9 
Total 2,714 100.0 
Mean (±SD) 30.6(±25.2) 
Persistence with nonbiologic DMARDs (days) 
Mean (±SD) 190.2(±201.4) 
Pre-index glucocorticoid utilization
b 
Yes 821 30.3 
No 1,893 69.8 
Total 2,714 100.1 
Post-index glucocorticoid utilization
b 
Yes 1,760 64.9 
No 954 35.2 
Total 2,714 100.1 
Post-index pain medication utilization
c 
  62 
Table 3.2. Baseline descriptive statistics, cont.  
Yes 2,507 92.4 
No 207 7.6 
Total 2,714 100.0
 
Charlson Comorbidity Index score 
1 1,599 58.9 
2 783 28.9 
≥3 332 12.2 
Total 2,714 100.0 
 Mean (±SD) 1.6(±0.93) 
Rheumatologist 
 Yes 605 22.3 
 No 2,005 73.9 
 Missing 104 3.8 
 Total 2,714 100.0 
DMARD = disease modifying anti-rheumatic drugs; HCQ= hydroxychloroquine; LEF = leflunomide;  
MTX = methotrexate; PDC = proportion of days covered; SSZ = sulfasalazine 
a Totals may not equal 100.0 due to rounding 
b Glucocorticoids include both oral and injectables 
c Pain medications include both NSAIDs and opioid analgesics 
∞ Others include American Indian, Asian, and unknown 
 
3.3.1.3 Description and comparison of biologic DMARD starters and non-starters  
 Although not included in the original objectives, Table 3.3 shows the unadjusted 
bivariate comparison of biologic DMARD starters and non-starters. Biologic DMARD 
non-starters were (but not practically) older than starters (48.3(±10.3) vs. 47.3(±10.8) 
years, p=0.03) and there were significant differences in race/ethnicity, most notably with 
Caucasians and other categories (p=0.049).  When compared to biologic DMARD non-
starters, a higher proportion of biologic DMARD starters had claims for glucocorticoids 
during the pre-index period (28.2% vs. 36.3%, p<0.0001). Similar results were shown in 
the post-index period (60.1% vs. 78.7%, p<0.0001). Although both starter and non-starter 
groups had low comorbidities (median CCI=1), biologic DMARD starters had a higher 
mean CCI score than biologic DMARD non-starters (1.73(±0.99) vs. 1.56(±0.90), 
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p<0.0001). Regarding prescriber type, a larger proportion of biologic DMARD starters 
had a rheumatologist visit compared to biologic DMARD non-starters (26.6% vs. 24.1%, 
p=0.002). With respect to non-biologic DMARD type, there was a significant difference 
between the two groups (p<0.0001), but no differences regarding mono vs. dual therapy. 
Mean non-biologic DMARD adherence [(32.7%(±25.8%) vs. (17.2%(±14.7%)] and 
persistence [mean: 225.7(±220.1) vs. 178(±193.1) days ; median: 140.0 vs. 100.0 days)] 
were higher among starters than non-starters.   
Table 3.3.  Comparison of baseline characteristics by biologic DMARD 
initiation status  
 Biologic 
DMARD 
starters 
(N=695) 
Biologic 
DMARD non-
starters 
(N=2,019) p-value 
Age, Mean (±SD)
a
  47.3 (±10.8)  48.3 (±10.3) 0.03 
Females (%)
b
 622 (89.5) 1,796 (89.0) 0.69 
Race/ethnicity (%)
b 
  0.049 
Caucasians 183 (26.3) 447 (22.1)  
African Americans 75 (10.8) 211 (10.5)  
Hispanics 375 (54.0) 1,125 (55.7)  
Others 62 (8.9) 236 (11.7)  
Preindex glucocorticoid utilization (%)
b 
252 (36.3) 569 (28.2) <0.0001 
Postindex glucocorticoid utilization (%)
b 
547 (78.7) 1,213 (60.1) <0.0001 
Postindex pain medication utilization (%)
b 
644 (92.7) 1,863 (92.3) 0.74 
Charlson Comorbidity Index
c
 
   Median 
   Mean(±SD)
 
 
1.0 
1.73 (±0.99) 
 
1.0 
1.56 (±0.90) 
<0.0001 
Rheumatologist visit
b 
Yes 
No 
Missing 
 
185 (26.6) 
420 (60.4) 
90 (12.9) 
 
486 (24.1) 
1,519 (75.2) 
14 (0.7) 
0.002 
Non-biologic DMARD utilization (%)
b 
MTX 
SSZ 
HCQ 
LEF 
Dual therapy
 
 
445 (64.0) 
49 (7.1) 
73 (10.5) 
30 (4.3) 
98 (14.1) 
 
771 (38.2) 
311 (15.4) 
609 (30.2) 
56 (2.8) 
272 (13.5) 
<0.0001 
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Table 3.3.  Comparison of baseline characteristics by biologic DMARD 
initiation status, cont.  
Non-biologic DMARD therapy
b 
Monotherapy (%) 
Dual therapy (%)
  
 
597 (85.9) 
98 (14.1) 
 
1,747 (86.5) 
272 (13.5) 
0.68 
Adherence to non-biologic DMARD
a 
    Median 
    Mean(±SD) 
 
24.7 
32.7(±25.8) 
 
12.5 
17.2(±14.7) 
<0.0001 
Persistence to non-biologic DMARD
a 
    Median 
    Mean(±SD) 
 
140.0 
225.7(±220.1) 
 
100.0 
178.0(±193.1) 
<0.0001 
a t-test 
b Chi-square test  
c Mann-Whitney U-test 
 
3.3.2 Objective 2: Adherence and persistence by non-biologic DMARD type  
Objective 2 was to determine whether adherence and persistence differ by non-
biologic DMARD type (Table 3.4). LEF users had the highest mean adherence of 
37.2%(±27.5%) and dual therapy users had the lowest mean adherence at 
17.2%(±14.7%). ANOVA showed that there was a significant (p<0.0001) difference in 
adherence by non-biologic DMARD type. Duncan’s multiple comparisons tests revealed 
that MTX users were significantly more adherent than SSZ and dual therapy users 
[(35.7%(±26.9%); 21.3%(±18.9%); 17.2%(±14.7%), respectively], while adherence to 
MTX did not differ from LEF (37.2%(±27.5%)) and HCQ users (32.6%(±25.2%)). Table 
3.5 shows that there was a significant (p<0.0001) relationship between dichotomous 
adherence (PDC ≥ 70%) and non-biologic DMARD type. Therefore, the hypothesis 
below was rejected: 
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H2a: Adherence to methotrexate is significantly higher than adherence to other 
non-biologic DMARD types. Rejected  
 
Persistence was calculated with a gap period of 60 days, with sensitivity analyses 
using 45 and 90 days. Overall mean persistence was 190.2(±201.4) days, which was 
slightly over six months. When grace periods of 45 and 90 days were applied, the overall 
mean persistence was 162.2(±182.5) and 231.5(±225.4) days, respectively. With the gap 
period of 60 days, persistence ranged from 110.0(±123.8) days (SSZ users) to 
225.1(±230.0) days (LEF users). ANOVA showed that there was a significant (p<0.0001) 
difference among non-biologic DMARD type (see Table 3.4). Duncan’s test showed that 
SSZ users (110.0(±123.8) days) had significantly lower persistence than all other users. 
LEF user persistence was the longest and significantly longer than SSZ and dual therapy 
users. MTX users had the second longest persistence, and had similar persistence 
compared to others except for SSZ users. Therefore, the hypothesis below was rejected: 
H2b: Persistence to methotrexate is significantly higher than persistence to 
other non-biologic DMARD types. Rejected 
 
When a sensitive analysis with a 45-day gap period was performed, Duncan’s test 
revealed that LEF users (203.4(±212.4) days) were more persistent than HCQ users 
(163.8(±187.9) days). All other group comparisons remained the same as in the 60-day 
gap analysis. On the other hand, with a longer gap period of 90 days, LEF users had 
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significantly higher persistence than all other users. All other pairwise group comparisons 
were the same as those in the 60-day gap analysis.   
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Table 3.4.  ANOVA comparison of adherence and persistence (60-day gap period) 
by non-biologic DMARD type (N=2,714) 
Non-biologic DMARD 
type 
Adherence (%)
a
 
Mean(±SD) 
Persistent days
b
 
Mean(±SD) 
MTX 35.7%(±26.9%) 
b, c 
212.2 (±223.0)
f, g 
SSZ       21.3%(±18.9%) 
d
 110.0 (±123.8)
h
 
HCQ      32.6%(±25.2%) 
c
 195.1 (±205.4)
f, g
 
LEF      37.2%(±27.5%) 
b
 225.1 (±230.0)
f
 
Dual therapy      17.2%(±14.7%) 
d
 178.6 (±145.7)
g
 
F, p-value 58.30, p<0.0001 19.47, p<0.0001 
MTX=methotrexate; SSZ=sulfasalazine; HCQ=hydroxychloroquine; LEF= leflunomide 
a ANOVA test showed a significant difference (F=58.30, p<0.0001) 
b,c,d Like letters are not significantly different (Duncan’s multiple range test) 
 e ANOVA test showed a significant difference (F=19.47, p<0.0001) 
f,g,h Like letters are not significantly different (Duncan’s multiple range test) 
 
Table 3.5.  Chi-square comparison of adherence by non-biologic DMARD type 
(N=2,714) 
Non-biologic DMARD 
type 
Adherent 
N (%)
a
 
MTX (N=1,216) 176 (14.5%)
 
SSZ (N=360) 12 (3.3%) 
HCQ  (N=682) 70 (10.6%) 
LEF (N=86) 
     13 
(15.1%) 
Dual therapy (N=370) 4 (1.1%) 
  
X
2
, p-value 79.1, p<0.0001 
MTX=methotrexate; SSZ=sulfasalazine; HCQ=hydroxychloroquine;  
LEF= leflunomide 
aAdherence is defined as a PDC value of ≥70% 
3.3.3 Objective 3: Adherence and persistence by non-biologic DMARD therapy  
Objective 3 was to determine whether adherence and persistence (gap period of 60 
days) differ by non-biologic DMARD therapy (see Table 3.6). Monotherapy users were 
significantly more adherent than dual therapy users (32.7%(±25.8) vs. 17.2%(±14.7)). 
Mann Whitney U analyses were conducted and showed similar results. Using a cut-off 
value of 70% for adherence, a higher proportion of monotherapy users were adherent 
  68 
than dual therapy users (11.6% vs. 1.1%, chi-square=38.5, p<0.0001) (Table 3.7). 
Therefore, the hypothesis below was failed to reject: 
H3a: Adherence to non-biologic DMARD monotherapy is significantly 
higher than adherence to non-biologic DMARD dual therapy. Failed to 
reject 
Persistence between monotherapy and dual therapy non-biologic DMARD users 
was not significantly different (192.0(±208.8) days vs. 178.6(±145.7) days). Mann 
Whitney U analyses were conducted and showed similar results. Therefore, the following 
hypothesis was rejected:  
H3b: Persistence to non-biologic DMARD monotherapy is significantly 
higher than persistence to non-biologic DMARD dual therapy. Rejected 
Table 3.6.  T-test comparison of adherence and persistence by non-biologic 
DMARD therapy (N=2,714) 
Non-biologic DMARD 
therapy 
Adherence (%)
a
 
Mean(±SD) 
Persistent days
b
 
Mean(±SD) 
Monotherapy (N=2,344) 32.7(±25.8)
 
192.0(±208.8)
 
Dual therapy (N=370)       17.2(±14.7) 178.6(±145.7) 
   
t, p-value 16.56, p<0.0001 1.54, p=0.12 
Table 3.7.  Chi-square comparison of adherence by non-biologic DMARD therapy 
(N=2,714) 
Non-biologic DMARD 
therapy 
Adherent 
N (%)
a
 
Monotherapy (N=2,344) 271 (11.6%)
 
Dual therapy (N=370)       4 (1.1%) 
  
X
2
, p-value 38.5, p<0.0001 
aAdherence is defined as a PDC value of ≥70% 
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3.3.4 Objective 4: Time to initiation of biologic DMARDs by non-biologic DMARD 
type and therapy (or survival without biologic DMARDs) 
Objective 4 was to determine whether time to initiation of biologic DMARDs 
differs by non-biologic DMARD type and therapy. Regarding non-biologic DMARD 
type, the overall mean time to initiation of biologic DMARDs was 601.3(±240.8) days. 
Time to biologic DMARD initiation differed by as much as 140 days. Table 3.8 and 
Figure 3.1 show that among monotherapy users, MTX users had the shortest time to 
initiation, while HCQ users had the longest [539.7(±276.9) days; 680.2(±158.7) days, 
respectively]. Log-rank group pairwise comparisons with MTX were performed using the 
Šidák adjustment method. Results showed that time to initiation for MTX was 
significantly shorter than SSZ, HCQ, and dual therapy users (539.7(±276.9) days; 
670.2(±167.8) days; 680.2(±158.7) days; 605.0(±227.4) days, respectively). MTX and 
LEF users had similar mean times to initiation (539.7(±276.9) days; 541(±286.5) days, 
respectively). Therefore, the following hypothesis was rejected: 
H4a: Time to initiation of biologic DMARDs does not differ significantly 
by non-biologic DMARD type. Rejected 
 
On the other hand, Log-rank test showed that monotherapy and dual therapy users 
did not differ significantly in time to initiation of biologics (see Table 3.9 and Figure 3.2). 
Therefore, the following hypothesis was failed to reject: 
H4b: Time to initiation of biologic DMARDs does not differ significantly 
by non-biologic DMARD therapy. Failed to reject 
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Table 3.8. Log-rank comparison of time to initiation of biologic DMARDs by non-
biologic DMARD type (N=2,714) 
Non-biologic DMARD 
type 
Time to initiation (days)
a
 
Mean(±SD) 
MTX (N=1,216) 539.7(±276.9)
b 
SSZ (N=360)       670.2(±167.8)
c
 
HCQ (N=682)     680.2(±158.7)
d
 
LEF (N=86) 541.6(±286.5)
b
 
Dual therapy (N=370) 605.0(±227.4)
e
 
  
F, p-value 58.30, p<0.0001 
a Group pairwise comparisons with MTX were performed using the Šidák adjustment method 
b-e Like letters are not significantly different (Log-rank test) 
MTX=methotrexate; SSZ=sulfasalazine; HCQ=hydroxychloroquine; LEF= leflunomide 
 
Table 3.9.  Log-rank comparison of time to initiation of biologic DMARDs by non-
biologic DMARD therapy (N=2,714) 
Non-biologic DMARD 
therapy 
Time to initiation 
(days)
a
 
Mean(±SD) 
Monotherapy (N=2,344) 600.7(±242.9) 
Dual therapy (N=370) 605.0(±227.4) 
  
Chi-square, p-value 0.0387, p=0.8440 
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Figure 3.1. Time to initiation of biologic DMARDs by non-biologic DMARD type  
 
Figure 3.2. Time to initiation of biologic DMARDs by non-biologic DMARD 
therapy 
 
  72 
3.3.5.Objective 5. Likelihood of initiation of biologic DMARDs by non-biologic 
DMARD type and therapy 
Objective 5 was to determine if the likelihood of patients initiating biologic 
DMARDs differs by non-biologic DMARD type and therapy, while controlling for 
covariates: patient socio-demographics (age, gender, race), medication use patterns (i.e., 
non-biologic DMARD adherence and persistence, pain medication use, glucocorticoid 
use), and clinical characteristics (i.e., comorbidities, and rheumatologist visit). (Table 
3.10). The likelihood of patients initiating biologic DMARDs was significantly 
associated with non-biologic type and therapy, age, glucocorticoid use, and persistence. 
With respect to non-biologic DMARD type, SSZ and HCQ users were less likely to 
initiate biologic DMARDs compared to MTX users by 69.0% (OR=0.310; 95% 
CI=0.221-0.434;p<0.0001) and 79.9% (OR=0.201; 95% CI=0.152-0.265;p<0.0001), 
respectively. Dual therapy users were 39.1% less likely to initiate biologic DMARDs 
compared to monotherapy users (OR=0.609; 95% CI=0.463-0.803;p=0.0004). Therefore, 
the following two hypotheses were rejected: 
H5a: The likelihood of methotrexate users initiating biologic DMARDs is 
significantly higher than that of non-methotrexate users, while controlling 
for covariates. Rejected 
H5b: The likelihood of non-biologic DMARD dual therapy users initiating 
biologic DMARDs is significantly higher than that of non-biologic 
DMARD monotherapy users, while controlling for covariates. Rejected 
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With 1 year increase in age, patients were 1.6% less likely to start biologic 
DMARDs (OR=0.984; 95% CI=0.975-0.993;p=0.0006). Therefore, the following 
hypothesis was failed to reject: 
H5c: With every year increase in age, the likelihood of patients initiating 
biologic DMARDs will decrease significantly, while controlling for 
covariates. Failed to reject   
 
Glucocorticoid non-users were 53.8% less likely to start on biologic DMARDs 
than glucocorticoid users (OR=0.462; 95% CI=0.372-0.573;p<0.0001). Therefore, the 
following hypothesis was rejected: 
H5i: Glucocorticoid non-users are significantly more likely to initiate 
biologic DMARDs compared to glucocorticoid users, while controlling for 
covariates. Rejected 
 
Patients with CCI score of ≥3 (not those with CCI score of 2) were approximately 
1.6 times more likely to initiate biologic DMARDs than those with CCI score of 1 
(OR=1.618; 95% CI=1.228-2.132;p=0.0006). Therefore, the following hypothesis was 
rejected: 
H5j: With every unit increase in the Charlson Comorbidity Index score, the 
likelihood of initiating biologic DMARDs increases, while controlling for 
covariates. Rejected 
 
On the other hand, non-biologic DMARD type (LEF), gender, race, CCI (score of 
2), adherence to non-biologic DMARDs, pain medication use, and rheumatologist visit 
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were not significantly related to the likelihood of patients starting on biologic DMARDs. 
Therefore, the following hypotheses were rejected: 
H5d: Females are significantly more likely to initiate biologics compared 
to males, while controlling for covariates. Rejected 
H5e: Caucasians are significantly more likely to initiate biologic DMARDs 
compared to non-Caucasians, while controlling for covariates. Rejected 
H5f: Non-adherent (PDC < 70%) patients are significantly more likely to 
initiate biologic DMARDs compared to adherent patients, while 
controlling for covariates. Rejected 
H5g: With every day decrease in persistence, the likelihood of initiating 
biologic DMARDs increases significantly, while controlling for 
covariates. Rejected 
H5h: Pain medication users are more likely to initiate biologic DMARDs 
compared to pain medication non-users, while controlling for covariates. 
Rejected 
H5k: Patients seen by rheumatologists are significantly more likely to 
initiate biologic DMARDs compared to patients seen by non-
rheumatologists, while controlling for covariates. Rejected 
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Table 3.10.  Logistic regression of initiation of biologic DMARDs by non-biologic 
DMARD type (N=2,714) 
Non-biologic DMARD type Odds 
ratio 
95% CI Wald X
2 
p-value 
Non-biologic DMARD type 
SSZ 0.310 0.221-0.434 46.3 <0.0001 
HCQ 0.201 0.152-0.265 128.4 <0.0001 
LEF 0.817 0.509-1.312 0.70 0.40 
Non-biologic DMARD therapy 
Dual therapy 0.609 0.463-0.803 12.4 0.0004 
Covariates 
Age 0.984 0.975-0.993 11.9 0.0006 
Female 1.008 0.738-1.376 0.0023 0.96 
Race/ethnicity 
   African Americans 
   Hispanics 
   Others 
 
0.879 
0.951 
0.646 
 
0.625-1.237 
0.755-1.196 
0.455-0.918 
 
0.55 
0.19 
5.94 
 
0.46 
0.67 
0.015 
Glucocorticoid non-user 0.462 0.372-0.573 48.99 <0.0001 
Pain medication non-user 1.105 0.742-1.645 0.24 0.62 
Charlson comorbidity index 
2 
≥3 
 
1.223 
1.618 
 
0.987-1.517 
1.228-2.132 
 
3.38 
11.70 
 
0.066 
0.0006 
Non-adherent to nonbiologic 
DMARDs (PDC<70%) 
0.936 0.632-1.388 0.11 0.74 
Persistence to nonbiologic 
DMARDs 
1.001 1.000-1.001 4.5 0.034 
Rheumatologist visit 1.174 0.946-1.459 2.12 0.15 
Reference groups=MTX, monotherapy, male, Caucasians, glucocorticoid user, pain medication 
user, Charlson Comorbidity Index score=1, adherent to nonbiologic DMARD, non-rheumatologist 
visit 
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Table 3.11.  Results of hypotheses testing 
Objectives/ Hypotheses Result 
Objective 1: Describe patient socio-demographic (age, gender, race), medication use patterns [i.e., non-
biologic DMARD type, non-biologic DMARD therapy (i.e., monotherapy, dual therapy)], non-biologic 
DMARD adherence and persistence, pain medication use, glucocorticoid use], and clinical characteristics 
(i.e., comorbidities and rheumatologist visit). 
Objective 2: To determine whether adherence and persistence differ by non-biologic DMARD type. 
H2a: Adherence to methotrexate is significantly higher than adherence to other non-
biologic DMARD types 
Rejected 
H2b: Persistence to methotrexate is significantly higher than persistence to other non-
biologic DMARD types 
Rejected 
Objective 3: To determine whether adherence and persistence differ by non-biologic DMARD therapy. 
H3a: Adherence to non-biologic DMARD monotherapy is significantly higher than 
adherence to non-biologic DMARD dual therapy.
 
Failed to reject 
H3b: Persistence to non-biologic DMARD monotherapy is significantly higher than 
persistence to non-biologic DMARD dual therapy. 
Rejected 
Objective 4: To determine whether time to initiation of biologic DMARDs differs by non-biologic 
DMARD type and therapy. 
H4a: Time to initiation of biologic DMARDs does not differ significantly by non-biologic 
DMARD type.
 
Rejected 
H4b: Time to initiation of biologic DMARDs does not differ significantly by non-biologic 
DMARD therapy.
 
Failed to reject 
Objective 5: To determine if the likelihood of patients initiating biologic DMARDs differs by non-biologic 
DMARD type and therapy, while controlling for covariates: patient socio-demographics (age, gender, 
race), medication use patterns (i.e., non-biologic DMARD adherence and persistence, pain medication 
use, glucocorticoid use), and clinical characteristics (i.e., comorbidities, and rheumatologist visit). 
H5a: The likelihood of methotrexate users initiating biologic DMARDs is significantly 
higher than that of non-methotrexate users, while controlling for covariates. 
Rejected 
H5b: The likelihood of non-biologic DMARD dual therapy users initiating biologic 
DMARDs iswill be significantly higher than that of non-biologic DMARD monotherapy 
users, while controlling for covariates. 
Rejected 
H5c: With every year increase in age, the likelihood of patients initiating biologic 
DMARDs will decrease significantly, while controlling for covariates.   
Failed to reject 
H5d: Females are significantly more likely to initiate biologics compared to males, while 
controlling for covariates. 
Rejected 
H5e: Caucasians are significantly more likely to initiate biologic DMARDs compared to 
non-Caucasians, while controlling for covariates. 
Rejected 
H5f: Non-adherent (PDC < 70%) patients are significantly more likely to initiate biologic 
DMARDs compared to adherent patients, while controlling for covariates. 
Rejected 
H5g: With every day decrease in persistence, the likelihood of initiating biologic DMARDs 
increases significantly, while controlling for covariates. 
Rejected 
H5h: Pain medication users are more likely to initiate biologic DMARDs compared to pain 
medication non-users, while controlling for covariates. 
Rejected 
H5i: Non-glucocorticoid users are significantly more likely to initiate biologic DMARDs 
compared to glucocorticoid users, while controlling for covariates. 
Rejected 
H5j: With every unit increase in the Charlson Comorbidity Index score, the likelihood of 
initiating biologic DMARDs increases, while controlling for covariates. 
Rejected 
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Table 3.11.  Results of hypotheses testing, cont.  
Objectives/ Hypotheses Result 
H5k: Patients seen by rheumatologists are significantly more likely to initiate biologic 
DMARDs compared to patients seen by non-rheumatologists, while controlling for 
covariates.   
Rejected 
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Chapter 4: Discussion and Conclusion 
4.1 CHAPTER OVERVIEW 
This chapter provides a discussion of the study results. The chapter covers a brief 
review of study purpose, followed by a discussion of the study results with possible 
explanations. The chapter will conclude with study limitations, conclusions, and future 
directions for research.    
4.2  REVIEW OF STUDY PURPOSE 
The purpose of this study was to evaluate medication adherence and persistence 
of RA patients on non-biologic DMARD therapy, and to examine the socio-demographic 
and clinical factors associated with initiation of biologic DMARD therapy among Texas 
Medicaid recipients with RA. There are currently four studies that have examined non-
biologic DMARD utilization patterns among RA patients.
70,75-77
  Only two of them are 
large retrospective database-studies that examined Medicaid recipients.
75,76
 These two 
studies will primarily be used to compare with the present study results. Moreover, 
several other studies and two RA treatment guidelines will be referred to when 
comparing and explaining the findings for each of the study objectives.
12,15,16,20-22,87,89-
91,95,96
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4.3 STUDY OBJECTIVES 
4.3.1 Objective 1 
Objective 1 was to describe patient socio-demographic, medication use patterns 
and clinical characteristics. The majority of subjects were female (89.1%) and 
mean(±SD) age of 48.1(±10.4). This was expected as being female is one of the risk 
factors for RA. While the literature suggests a higher mean age of 67,
6
 the above mean 
age was lower due to this study’s inclusion criteria which limited subjects to ≤63 to avoid 
inclusion of dual eligible patients. The mean age was lower compared to that in the 
Tennessee (TN) Medicaid study in which the mean age ranged from 51 to 58 by 
DMARD regimen type.
75
 Thus, the present study is one of the few studies that have 
examined non-elderly. As would be expected in Texas, over half of the study sample was 
Hispanic (55.3%). This differed from the previous TN Medicaid studies where over 70% 
of subjects were Caucasian. Otherwise, gender was similar between the TN and TX 
Medicaid studies.  
As for the non-biologic DMARD use, the plurality of subjects (44.8%) was on 
MTX, followed by HCQ (25.1%). The order of prevalence was nearly identical in the TN 
Medicaid studies in which MTX was most commonly used (37%), followed by HCQ 
(30%).
75
 The prevalent use of MTX was expected as it is the drug of choice 
recommended by both ACR and EULAR treatment guidelines.
15,16
 Adherence to non-
biologic DMARDs was low, with 10.1% of subjects who were adherent (PDC≥70%) to 
their therapy. The mean(±SD) adherence rate was 30.6±25.2%, and was in the lower 
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range of 33 – 107% adherence rates in previous studies.70,75-77 The present study observed 
a lower adherence rate compared to previous studies for the following potential reasons: 
differences in adherence measurement methods (PDC vs. MPR, MEMS, pill counts), 
study medication regimens, and follow-up periods (2 years vs.  42 months – 10 years). 
PDC is one of the more conservative methods for measuring adherence. In addition, 
longer follow-up periods typically lead to higher discontinuation and lower adherence to 
therapies compared to shorter follow-up periods. The mean(±SD) persistence with non-
biologic DMARDs was slightly over six months [190.2(±201.4) days] during the 2-year 
follow-up period. This suggests that subjects were either switching to other non-biologic 
DMARD regimens or initiating biologics. Persistence was not comparable to previous 
studies because they had longer follow-up periods than the current study.
20,22,23,75
  
Regarding other non-DMARD use, GC use more than doubled from pre-index 
(30.3%) to post-index (64.9%) period. This was likely as GCs are usually given in 
combination with non-biologic DMARDs to slow down RA progression. GC use was 
reported in the TN Medicaid study, which ranged from 26 to 48% depending on DMARD 
regimen type, and was similar to the present study’s pre-index GC use. The majority of 
subjects (92.4%) used pain medication while taking non-biologic DMARDs; nearly 30% 
of subjects (32.5%) were on opioid pain medications while 59.9% were on non-opioid 
pain medications (including both NSAIDs and acetaminophen). The high percentage of 
pain medication use was also expected since most RA patients are in need of pain relief. 
Pain medication utilization, although defined differently, seemed to be within the range 
of the TN Medicaid subjects where 35 – 59% of them were prescribed opioid pain 
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medications, and, 32 – 44% were prescribed NSAIDs.75 The current study’s comorbidity 
measure (i.e., CCI) was similar (nearly 90% had CCI score equal to 1 or 2), to what was 
previously reported (≥2 comorbid conditions).12 Lastly, most subjects were seen by non-
rheumatologists (73.9%), which suggests that the majority of RA patients initially seek 
medical assistance from general practitioners. This was not consistent with the 
recommendation by the EULAR that states that RA patients should primarily be cared by 
rheumatologists for early diagnosis, optimal therapy management, and better outcomes.
16
 
Previous literature shows conflicting reports on the difference in RA outcomes between 
rheumatologists and general practitioners. While Singh et al. suggested that RA care by 
rheumatology nurses and general practitioners are as effective as care by rheumatologist, 
van der Linden MP et al. showed that RA patients’ earlier assessments by a 
rheumatologist are more likely to achieve better disease outcomes.
24,97-99
  
When an unadjusted bivariate comparison was made between biologic DMARD 
starters and non-starters, biologic DMARD non-starters were older. This was anticipated 
because older patients are more likely to be vulnerable to immunosuppressant properties 
of biologic DMARDs, thus less likely to initiate biologic DMARDs. A study by Dewitt et 
al. also showed that older age was associated with a lower likelihood to initiate biologic 
DMARDs.
100
 Among the TN Medicaid population, however, new users of biologic 
DMARDs were observed to be older (>55 years) than new users of non-biologic 
DMARDs. Although not addressed in the study, this may suggest another view that 
because older but non-elderly patients tend to have higher RA severity than younger 
patients, they may require more aggressive biologic therapies. While both biologic 
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DMARD starters and non-starters were predominantly females in similar proportions, 
they were different in terms of race. The similar prevalence of females was expected as 
suggested by the study by Dewitt et al.
100
 In terms of race, Caucasians comprised a 
slightly higher proportion in the biologic DMARD starter group than the non-starter 
group (26.3% vs. 22.1%). In the largest category of race, Hispanics, the percentage of 
biologic DMARD starters was slightly lower than non-starters (54.0% vs. 55.7%). 
Because of the unique race/ethnicity distribution of Texas Medicaid and our specific 
study groups, the results cannot be compared to other studies. Regarding non-DMARD 
use, biologic DMARD starters were higher in GC use during both preindex and postindex 
periods. This was a predictable trend as GCs are commonly used in combination with 
biologic DMARDs as noted by the EULAR recommendations.
16
 In addition, higher GC 
use in preindex period among biologic DMARD starters may indicate that the group had 
more severe RA at baseline compared to the non-starter group. There was no difference 
in pain medication use between the two groups. Biologic DMARD starters had a higher 
CCI score than non-starters (1.73(±0.99) vs. 1.56(±0.90)); however, this may not present 
a clinically significant difference. A higher proportion of biologic DMARD starters was 
seen by a rheumatologist compared to biologic DMARD non-starters (30.6% vs. 24.2%), 
which may suggest that rheumatologists are more aggressive in treating RA patients.  
As for non-biologic DMARD utilization, there were significant differences among 
the five medication types; a higher proportion of biologic DMARD starters used MTX, 
LEF, and dual therapy, while a lower proportion used SSZ and HCQ compared to non-
starters. Such a different trend by starter and non-starter groups was not anticipated. The 
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expectation was that there would be no particular utilization differences between the two 
groups with regards to medication type. This may be explained by different prescribing 
patterns by RA severity. In both starter and non-starter groups, the majority of subjects 
were non-biologic DMARD monotherapy users in similar percentages. Regarding 
adherence and persistence to non-biologic DMARDs, biologic DMARD starters were 
more adherent and persistent (to their non-biologic DMARD) than non-starters. Biologic 
DMARD starters may have been more aggressive in treating RA compared to non-
starters. Overall, biologic DMARD starters tended to be younger in age, more likely to be 
Caucasian, more likely to take MTX or LEF, more adherent and persistent to their non-
biologic DMARD, more likely to take glucocorticoids, higher in CCI, and likely to visit a 
rheumatologist when compared to biologic DMARD non-starters. Although not 
examined, RA severity may also play a role in the likelihood of starting a biologic 
DMARD. Furthermore, this study is unique in that it examined a younger population and 
one with a higher percentage of Hispanics compared to other studies.  
4.3.2 Objective 2 
Objective 2 was to determine whether adherence and persistence differed by non-
biologic DMARD type. Overall, mean adherence was low across the non-biologic 
DMARD users, ranging from 17.2%(±14.7) to 37.2%(±27.5). Adherence was highest in 
the LEF user group, followed by MTX, HCQ, SSZ, and dual therapy user groups. The 
adherence comparison was similar to what was shown in previous studies conducted in 
TN Medicaid population: LEF and MTX with higher adherence with similar rates and 
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SSZ with lower adherence than others.
1,2
 This trend was expected as MTX is usually the 
drug of choice because it has a low side effect profile with long-term use. LEF is another 
preferred drug after MTX as suggested by a study that showed similar effectiveness 
between LEF and MTX.
97
 On the other hand, dual therapy users had the lowest 
adherence. This can be explained by the fact that taking more than one medication takes 
more effort, especially if the medications have different dosing schedules. SSZ users had 
the second lowest adherence, which was also observed in a previous study.
76
 SSZ users 
may be less adherent than other medication users because it is taken twice daily as 
opposed to an easier once-daily dosing schedule. Another study by de Klerk et al. also 
demonstrated that MTX had higher adherence and SSZ had lower adherence.
70
 Regarding 
persistence, LEF users had the longest persistence, followed by MTX, HCQ, dual 
therapy, and SSZ users, which was in a similar order as adherence. During the 2-year 
follow up period, LEF and MTX users similarly had an average persistence of over 7 
months, and SSZ with the shortest persistence of a little over 3 months. In previous 
studies, MTX had the highest persistence and SSZ with the lowest persistence.
20-23,95,96
 
One study reported a different result that while MTX users had the highest persistence, 
LEF users had lower persistence than SSZ users.
21
 With a low side effect profile, it is 
expected that MTX users would have higher persistence than others. A meta analysis 
revealed that HCQ and SSZ were discontinued mostly due to inefficacy.
95
 Furthermore, 
Aletaha et al. showed that higher dose therapy was associated with longer persistence 
among MTX and SSZ users. This suggests that a higher dose, which results in higher 
effectiveness, leads to better persistence with therapy. This association could not be 
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confirmed with the present study as dose was not measured. It will be worthwhile to 
further explore the relationship in the future.    
4.3.3 Objective 3 
Objective 3 was to determine whether adherence and persistence differ by non-
biologic DMARD therapy. Non-biologic DMARD monotherapy users were significantly 
more adherent than dual therapy users. This was consistently observed whether adherence 
was measured continuously or dichotomously. While the study by Grijalva et al. had 
different dual therapy regimens consisting of a non-biologic and a biologic DMARD, the 
study results revealed a similar pattern of having low mean adherence among dual non-
biologic DMARD therapy users compared to monotherapy users. This shows that 
regardless of the medication type, taking two medications affects patients’ medication 
taking behavior. When comparing persistence with non-biologic DMARD therapy, 
monotherapy users had longer days of persistence than dual therapy users but the results 
were not significantly different (192.0(±208.8) vs. 178.6(±145.7) days; p=0.12), which 
was consistent with previous studies.
20,75
 This may imply that persistence is not 
associated with therapy (e.g., mono vs. dual) whereas adherence was in this study. 
Instead, as shown in objective 2, individual medication type affects persistence. 
Additionally, wide variations (i.e. large standard deviations) associated with persistence 
may have impacted significance tests (i.e. power). 
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4.3.4  Objective 4 
Objective 4 was to determine whether time to initiation of biologic DMARDs 
differs by non-biologic DMARD type and therapy. When stratified by non-biologic 
DMARD type, MTX users had the shortest time to initiation, followed by LEF, dual 
therapy, SSZ, and HCQ users who had the longest time to initiation. There was a mean 
difference of 140 days for time to initiation between MTX and HCQ groups. 
Interestingly, there was an inverse relationship between non-biologic DMARD 
persistence and time to initiation of biologic DMARDs. MTX and LEF users had similar 
longer persistence and shortest time to initiation; SSZ users had the shortest persistence 
and second longest time to initiation in the study. This may indicate that those with 
higher persistence were more active in treating their disorder, which may have indicated 
more morbidity associated with their RA, and thus faster to initiate biologic DMARDs. 
By contrast, those who had shorter persistence may not have been as severe and, thus, 
time to initiate biologic DMARDs was longer. However, there may be other factors that 
could have affected time to initiation of biologic DMARDs. For instance, clinical 
parameters were not available to control for disease severity, which could confound the 
relationship. Clinical factors should be taken into consideration to re-examine this 
association in future studies. In terms of non-biologic DMARD therapy, there was no 
difference between time to initiation of biologic DMARDs between non-biologic 
DMARD monotherapy and dual therapy users. This suggests that time to initiation to 
biologic DMARDs is affected by individual medication type rather than medication 
therapy category.   
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4.3.5  Objective 5 
Objective 5 was to determine if the likelihood of patients initiating biologic 
DMARDs differs by non-biologic DMARD type and therapy, while controlling for 
covariates: patient socio-demographics (age, gender, race), medication use patterns (i.e., 
non-biologic DMARD adherence and persistence, pain medication use, glucocorticoid 
use), and clinical characteristics (i.e., comorbidities, and rheumatologist visit). SSZ and 
HCQ users were less likely to initiate biologic DMARDs compared to MTX users. As 
shown in objectives 2 and 4, MTX users had relatively higher adherence and persistence 
to non-biologic DMARDs than others; this may signify that the MTX user group may 
have had more severe RA and thus were motivated to adhere and seek additional 
treatment. Unexpectedly, non-biologic DMARD dual therapy users were less likely to 
start on biologic DMARDs when compared to monotherapy users. This relationship 
requires further investigation, but it may be likely that the use of two therapies was 
effective enough to delay biologic DMARD initiation. The associations between younger 
age and GC use, and higher likelihood of initiating biologic DMARDs was consistent 
with another study result by Dewitt et al.
100
 While higher CCI (i.e., CCI ≥3)was 
associated with higher likelihood of starting biologic DMARDs, Dewitt et al. did not find 
any significant association with comorbidity, which was defined differently as reported 
comorbidities. Certain comorbid disorders (e.g., congestive heart failure, sepsis, 
tuberculosis) are known to delay or prevent patients from starting biologic DMARDs. 
However, we did not control for these individual conditions. This study’s finding 
suggests that having high comorbid levels may increase the likelihood of initiating 
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biologic DMARDs because of more pain and extra-articular complications. In addition, 
previous studies demonstrated that higher disability and DAS scores were associated with 
a higher likelihood of starting biologic DMARDs.
87,89,91,100
  
4.4 STUDY LIMITATIONS 
Several study limitations that may affect the study results are discussed next. 
First, the study utilized PDC as a proxy for measuring medication adherence. PDC does 
not reflect an actual adherence as subjects may have not taken the filled prescriptions as 
assumed in the study. Second, for those who were switching and/or stepping up and down 
from non-biologic DMARD therapy, they were estimated to be either monotherapy or 
dual therapy users as defined in the study. There were several assumptions in defining 
non-biologic DMARD monotherapy and dual therapy. Dual therapy was defined as 
having two non-biologic DMARDs filled with two overlapping periods of at least 15 
days, with the first claim filled within 4 months of the index date. There may have been 
subjects categorized as monotherapy users instead of dual therapy users because of the 
stringent definition. Third, using the retrospective claims database precluded access to 
other relevant information such as clinical data (e.g., RA disease activity level, pain 
assessment). Including such clinical variables would make the analyses more robust 
because RA severity could be controlled. Furthermore, because there was no data on the 
days supply for MTX injectables in the database, dosing intervals were assumed 
depending on the dose in data analysis. Finally, the study findings are only generalizable 
to the Texas Medicaid population. 
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4.5  CONCLUSIONS AND SUGGESTIONS FOR FUTURE RESEARCH 
The main purpose of this study was to examine the factors associated with 
initiation of biologic DMARDs. The study results showed that younger age, GC use, 
MTX user (vs. SSZ, HCQ users) and non-biologic DMARD monotherapy user (vs. dual 
therapy user) were significantly associated with initiation of biologic DMARDs. Unlike 
the expectation, adherence and persistence to non-biologic DMARDs were not shown to 
be predictors of initiation of biologic DMARDs. In addition, regarding the time to 
initiation of biologic DMARDs, MTX users took the shortest time and HCQ users took 
the longest time to initiate biologic DMARDs among the five types of non-biologic 
DMARD therapy users. To further investigate these associations, other pertinent factors, 
such as patients’ attitudes/behaviors toward their medications and disorder and disease 
severity, should also be taken into account in future studies.  
The secondary purpose of the study was to evaluate adherence and persistence of 
non-biologic DMARD therapy users. The overall adherence rate was low with only 
10.1% of subjects being adherent (PDC≥70%) to non-biologic DMARDs. LEF and MTX 
users had similarly the highest mean adherence and persistence, while non-biologic 
DMARD dual therapy users had the lowest adherence and SSZ with the lowest 
persistence. For future research, it would be worthwhile to further examine the 
associations between adherence and/or persistence and health outcomes (i.e., clinical and 
economic outcomes).  
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Both clinicians and the Texas Health and Human Services Commission should 
recognize the potential driving factors of initiation of biologic DMARDs in this 
population with RA. Clinicians should take efforts to monitor for effective pain 
medication and GC use to better control for RA symptoms (e.g., using long-acting 
formulations of NSAIDs or delayed release formulation of GCs). They should thoroughly 
evaluate current non-biologic DMARD therapy users and consider dual therapy before 
stepping up to biologic DMARDs. This study showed that those more likely to initiate 
biologic DMARDs had the following characteristics: female, younger age, MTX user, 
non-biologic DMARD monotherapy user, and GC user. Providers may want to focus on 
this group specifically to identify needs and provide treatment and education that will 
lead to optimal RA therapy. Medicaid should promote well-structured RA monitoring 
programs for patients to effectively receive optimal therapy and to ensure appropriate use 
of expensive biologic DMARD therapies. In addition, they should also invest in patient 
education programs to enhance medication adherence and persistence to RA medications.  
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Appendix A. List of Abbreviations 
 
ACR: AMERICAN COLLEGE OF RHEUMATOLOGY 
DMARD: DISEASE-MODIFYING ANTIRHEUMATIC DRUG 
EULAR: EUROPEAN LEAGUE AGAINST RHEUMATISM  
GC: GLUCOCORTICOID 
HCQ: HYDROXYCHLOROQUINE 
LEF: LEFLUNOMIDE 
MTX: METHOTREXATE 
PDC: PROPORTIONS OF DAYS COVERED 
SSZ: SULFASALAZINE  
TNF: TUMOR NECROSIS FACTOR  
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